
This is the author’s final accepted version.

There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

[http://eprints.gla.ac.uk/157305/](http://eprints.gla.ac.uk/157305/)

Deposited on: 27 February 2018
Colorectal tumors require NUAK1 for protection from oxidative stress

Jennifer Port1*, Nathiya Muthalagu2*, Meera Raja1, Fatih Ceteci2, Tiziana Monteverde1, Bjorn Kruspig1, Ann Hedley2, Gabriela Kalna2, Sergio Lilla2, Lisa Neilson2, Martina Brucoli1, Katarina Gyuraszova1, Jacqueline Tait-Mulder1, Mokdad Mezna3, Silvija Svambaryte1, Amy Bryson1, David Sumpton2, Allan McVie1, Colin Nixon2, Martin Drysdale3, Hiroyasu Esumi4, Graeme I. Murray5, Owen J. Sansom1,2, Sara R. Zanivan1,2 & Daniel J. Murphy1,2§

1 Institute of Cancer Sciences, University of Glasgow, UK
2 CRUK Beatson Institute, Garscube Estate, Switchback Rd. Glasgow, G61 1BD
3 Drug Discovery Unit, CRUK Beatson Institute, Glasgow, UK
4 National Cancer Center Hospital, Kashiwa, Chiba, Japan
5 Dept. of Pathology, University of Aberdeen, UK

* Equal contributors

§ To whom correspondence should be addressed:
   Email: daniel.murphy@glasgow.ac.uk
   Phone: +44 141 330 8710

The authors declare no conflict of interest in the submission of this manuscript.

Word Count: 5792 exclusive of Abstract, References & Figure Legends.
Abstract
Exploiting oxidative stress has recently emerged as a plausible strategy for treatment of human Cancer and anti-oxidant defences are implicated in resistance to chemo- and radiotherapy. Targeted suppression of anti-oxidant defences could thus broadly improve therapeutic outcomes. Here we identify the AMPK-related kinase NUAK1 as a key component of the anti-oxidant stress response pathway and reveal a specific requirement for this role of NUAK1 in colorectal cancer. We show that NUAK1 is activated by oxidative stress and that this activation is required to facilitate nuclear import of the anti-oxidant master regulator NRF2: Activation of NUAK1 coordinates PP1β inhibition with AKT activation in order to suppress GSK3β-dependent inhibition of NRF2 nuclear import. Deletion of NUAK1 suppresses formation of colorectal tumors, while acute depletion of NUAK1 induces regression of pre-existing autochthonous tumors. Importantly, elevated expression of NUAK1 in human colorectal cancer is associated with more aggressive disease and reduced overall survival.

Significance
This work identifies NUAK1 as a key facilitator of the adaptive anti-oxidant response that is associated with aggressive disease and worse outcome in human CRC. Our data suggest that transient NUAK1 inhibition may provide a safe and effective means for treatment of human CRC via disruption of intrinsic anti-oxidant defences.

Keywords
NUAK1; ARK5; NRF2; Oxidative stress; Metabolic stress; Colorectal Cancer; Cancer Therapy
Introduction

The relentless drive to proliferate exposes tumor cells to considerable metabolic stress. Proliferating tumor cells increase nutrient consumption in order to balance the competing demands of macromolecular synthesis, towards which a large proportion of nutrient metabolites are diverted, with the energetic cost of sustaining viability, measured in ATP (1). Increased metabolic activity elevates production of reactive oxygen species (ROS), altering signal transduction and, at very high levels, inflicting damage upon lipids, proteins and nucleic acids (2). In the context of a growing solid tumor with ineffective vascularity, tumor cells are commonly deprived of their preferred nutrients and exposed to hypoxia, which also increases ROS production, adding cell-extrinsic sources of further metabolic stress. In order to survive such stress, tumor cells must adapt flexibly and continuously by modulating their rates of macromolecular synthesis, cell growth, and proliferation, in order to maintain ATP homeostasis and counteract ROS. Failure to do so leads to ATP collapse, toxic levels of ROS, and loss of viability. As such, targeted suppression of adaptive measures used by tumor cells to counteract metabolic stress may yield therapeutic benefit in cancer treatment.

NUAK1 (aka ARK5) is one of 12 kinases related by sequence homology to the catalytic α subunits of AMPK (3). Collectively, these kinase play various roles in regulating cell adhesion and polarity, cellular and organismal metabolism, and in the cellular response to various forms of stress, including oxidative, osmotic and energetic stress (4, 5). NUAK1 is a common target of several miRNAs that are frequently suppressed in cancer, suggesting a potential role for NUAK1 in tumorigenesis (6-8). Accordingly, we previously reported that NUAK1 is required to sustain viability of cancer cells when MYC is overexpressed (9).

In contrast with the widely studied AMPK, the molecular targets and downstream pathways governed by NUAK1 are poorly defined. To date, the best-characterized substrate of NUAK1 is the PP1β subunit, MYPT1 (PPP1R12A). During cell detachment, phosphorylation of
MYPT1 by NUAK1 inhibits PP1β phosphatase activity towards myosin light chain. Inhibition of NUAK1 thus increases PP1β activity, delaying cell detachment and suppressing cell migration (10). Other work points to a role for NUAK1 in metabolic regulation. Muscle-specific deletion of Nuak1 protects mice from high fat diet-induced diabetes, attributable to increased glucose uptake and increased conversion of glucose to glycogen by Nuak1-deficient skeletal muscle (11). An earlier study showed that NUAK1 protects cancer cells from nutrient deprivation-induced apoptosis (12). In the context of MYC overexpression, we showed that NUAK1 is required to maintain ATP homeostasis, in part by facilitating AMPK-dependent inhibition of TORC1-driven macromolecular synthesis (9, 13). Failure to engage this checkpoint results in cell death under conditions of metabolic stress (14-16).

Our previous work thus suggested that NUAK1 may present a good target for therapy, specifically in the context of MYC-driven cancers. Human colorectal cancer (CRC) is uniformly characterized by deregulated expression of MYC and mouse models have shown that expression of endogenous Myc is required for intestinal polyp formation upon loss of Apc, the most common tumor-initiating event in human CRC (17, 18). We asked therefore if NUAK1 is required to support tumor cell viability in CRC. Here we show that NUAK1 is overexpressed in human CRC and that high NUAK1 expression correlates with reduced overall survival. Using genetically engineered mouse models of CRC driven by sporadic loss of Apc, we show that NUAK1 is required for both initiation and maintenance of autochthonous colorectal tumors. NUAK1 facilitates nuclear translocation of the anti-oxidant master regulator NRF2 by counteracting negative regulation of NRF2 by GSK3β. Depletion or inhibition of NUAK1 thus renders human CRC cells and murine colorectal tumors vulnerable to oxidative stress-induced cell death. Our data reveal NUAK1 as a candidate therapeutic target in human CRC.
Results

*Nuak1 overexpression is associated with worse outcome in human CRC*

We used RNA-Scope in situ hybridization to examine *NUAK1* expression in a 660-sample tissue microarray of human CRC (19). *NUAK1* is weakly expressed in normal human colonic epithelium but increased expression is significantly enriched in aggressive (Dukes’ stage B & C) CRC (Fig. 1A & S1A, B). *In silico* examination of the TCGA Colorectal adenocarcinoma cohort similarly showed significantly elevated *NUAK1* expression in advanced (T stage 3 & 4) versus early (T stage 1 & 2) disease, and in patients with lymph node metastasis versus none (Fig. 1B). Meta-analysis of 17 independent cohorts comprising 947 human CRC samples, via SurvExpress (20), also revealed significantly higher *NUAK1* expression in the high versus low risk group, and elevated *NUAK1* expression was associated with significantly reduced overall survival and a hazard ratio of 1.49 (Fig. 1C, D). A similar reduction of overall survival was borne out by individual analysis of two large cohorts in which the outcome for the majority of patients was known (Fig. S1C-F) (21, 22). Elevated *NUAK1* expression thus correlates with worse outcome in colorectal cancer.

We therefore examined the functional requirement for NUAK1 in human CRC cell lines using 2 previously described highly-selective NUAK1 inhibitors, HTH-01-015 and WZ4003. HTH-01-015 is reported to show little-to-no activity towards AMPK or other related kinases while WZ4003 selectively inhibits both NUAK1 and the closely related NUAK2 (23). Overexpression of NUAK1 and NUAK2 in human CRC tends to be mutually exclusive and accordingly we detected a reciprocal pattern of NUAK protein expression in CRC cell lines (Fig. S1G, H). Treatment with 5µM HTH-01-015 suppressed proliferation of multiple cell lines and this effect was reproduced by RNAi-mediated depletion of NUAK1 (Fig. S1I-L). Strikingly, treatment with 10µM HTH-01-015 was profoundly toxic in the same cell lines and correlated with a stronger reduction in phosphorylation of the NUAK1/NUAK2 substrate, MYPT1, even in cells that express very low levels of NUAK1 (Fig. 1E, F). This cytotoxic effect was also observed using the dual NUAK inhibitor WZ4003, suggesting it
reflects on-target activity of the inhibitors. Notably, WZ4003 gave greater suppression of p-MYPT1 though, consistent with dual inhibition of NUAK1 and NUAK2, and showed somewhat greater potency, driving significant cell death at 5µM in SW480 cells (Fig. S1M, N). Inhibition of NUAK1 is thus sufficient to drive apoptosis in CRC cells and death does not require complete suppression of p-MYPT1. In contrast with the CRC lines, wild-type MEFs and U2OS cells were comparatively resistant to both inhibitors, especially to the NUAK1-selective HTH-01-015 (Fig 1G & S1O, P), consistent with previous data showing that U2OS are refractory to NUAK1 depletion (9). Notably, both inhibitors completely suppressed MYPT1 phosphorylation in U2OS, indicating that NUAK1 accounts for the vast majority of MYPT1 phosphorylation in this cell type. As we showed previously in MEFs (5), overexpression of MYC strongly sensitized U2OS to HTH-01-015-induced apoptosis (Fig. 1H). Conversely, depletion of endogenous MYC rescued CRC cells from HTH-01-015-induced apoptosis and rescue was proportional to the degree of MYC depletion, consistent with an ectopic requirement for NUAK1 in cells with deregulated MYC (Fig. 1I).

**Nuak1 is required for formation of colonic polyps in mice**

In order to investigate the in vivo requirement for NUAK1 in CRC, we bred mice bearing a floxed Nuak1 allele (Nuak1fl/fl) onto a Tamoxifen (Tam)-inducible mouse model of sporadic intestinal cancer: \( \text{Villin-CreER}^{T2}; \text{APC}^{fl/+}; \text{Isl-KRas}^{G12D} \) (VAK for short). In this model, transient Tam-dependent activation of CreER\(^{T2}\) in the intestines of adult mice drives widespread deletion of one copy of Apc simultaneous with expression of oncogenic KRas\(^{G12D}\), however, tumor formation requires stochastic loss of the second copy of Apc (Fig. S2A). In the absence of mutant KRas, Apc null polyps are largely restricted to the small intestine, whereas in the presence of mutant KRas, adenomas form in both large and small intestine (19).

Using a single injection of Tam to transiently activate CreER\(^{T2}\), we deleted Nuak1 in the intestines of adult \( \text{Villin-CreER}^{T2}; \text{APC}^{fl/+}; \text{Isl-KRas}^{G12D}, \text{Nuak1}^{fl/fl} \) mice (VAKN for short) and aged
mice until symptomatic in order to compare the intestinal tumor burden with that of symptomatic VAK mice. Deletion of *Nuak1* profoundly suppressed both the number and size of individual tumors in the colon of VAKN mice, compared to VAK controls (Fig. 2A-D). In contrast, we observed no significant difference in either the number or size of tumors that arose in the small intestine (SI), and VAKN mice required sacrifice concurrently with VAK mice (Fig. S2B-D). However, Q-PCR analysis of *Nuak1* expression in individual polyps harvested from the SI of VAKN mice revealed enrichment of *Nuak1* mRNA when compared with disease-free adjacent tissue (Fig. S1E), indicating a failure of transient CreER activation to efficiently delete *Nuak1* in the tumor initiating population of the small intestine. The absence of a *Nuak1* FL/FL phenotype in SI tumors thus appears to reflect technical failure but is of little clinical relevance given the rarity of SI tumors in human populations. Colonic tumors in VAKN mice presented with comparable levels of nuclear β-Catenin and sporadic phospho-Erk1/2 staining, as compared with VAK tumors (Fig. S2F), however, all tumors arising in VAKN mice retained detectable expression of *Nuak1* mRNA (see Fig. S2G for examples), suggesting a selective pressure to retain Nuak1 in colonic tumor epithelium. Importantly, deletion of *Nuak1* in otherwise wild-type mice had no apparent effect on small or large intestine architecture or function (Fig. S3A-C), suggesting that the requirement for Nuak1 in the adult gut is restricted to transformed tissue.

**Nuak1 activity is required for ex-vivo spheroid formation**

Homozygous deletion of *Apc* (A\(^{\text{Hom}}\)) in the gut rapidly gives rise to a Myc-dependent “crypt progenitor” phenotype, characterized by an extension of the transit-amplifying population into the normally quiescent villi of the small intestine (17). This phenotype was unimpaired by deletion of *Nuak1* in VA\(^{\text{Hom}}\)N intestines (Fig. S3D). VA\(^{\text{Hom}}\)K transformed gut epithelium gives rise to spheroids when cultured in 3D ex vivo, reflecting the tumor-initiating capacity of the transformed tissue (24). Primary VA\(^{\text{Hom}}\)KN colonic epithelium showed reduced spheroid-generating capacity,
compared to VA\textsuperscript{HomK} epithelium (Fig. 2E & F). Nuak1 expression was clearly detectable in the few VA\textsuperscript{HomKN} spheroids that grew, suggesting that they likely arose from cells that escaped Cre-mediated \textit{Nuak1} deletion (Fig. 2G). Interestingly, a similar reduction in spheroid-generating capacity was also observed in primary epithelium isolated from the small intestine (Fig. 2E & F). Accordingly, pharmacological inhibition of Nuak1 with either HTH-01-015 or WZ4003 profoundly suppressed formation of spheroids by VA\textsuperscript{HomK} gut epithelium from both small and large intestine (Fig. 2H & I), whereas wild-type organoids were refractory to treatment over the same time frame (Fig. S3E).

\textit{NUAK1 regulates the NRF2-dependent oxidative stress response}

Reasoning that key physiological roles of NUAK1 would be conserved across cell types, we exploited the fact that U2OS cells are refractory to NUAK1 suppression (in the absence of MYC overexpression) and express very little NUAK2, and performed an unbiased transcriptomic analysis after RNAi-mediated depletion of NUAK1. Metacore GeneGO pathway analysis revealed regulation of cholesterol synthesis, cell adhesion, and glutathione metabolism amongst the topmost pathways modulated upon NUAK1 depletion (Fig. 3A). The role of NUAK1 in regulating cell adhesion via phosphorylation of MYPT1 was described previously (10), while the modulation of glutathione metabolism suggested a novel role for NUAK1 in the anti-oxidant defense pathway. Strikingly, our transcriptomic analysis revealed a coordinated reduction in expression of a host of genes that are regulated by the anti-oxidant transcription factor NRF2 (\textit{NFE2L2}) (25), including the catalytic and regulatory subunits of the Glutamate-Cysteine Ligase; ROS scavengers Thioredoxin, Peroxiredoxin and MGST; and Glutathione Reductase (Fig. 3B & S4A). Acute inhibition of NUAK1 in U2OS cells with HTH-01-015 recapitulated these results (Fig. 3C), as did CRE-mediated deletion of \textit{Nuak1} in primary MEFs (Fig. S4B, C), confirming the conservation of this effect across cells types and species. RNA-SEQ analysis of SW480 CRC cells upon depletion of NUAK1 revealed a strong
overlap with genes modulated upon depletion of NRF2 (NFE2L2), including several anti-oxidant pathway genes and the miR17-92 cluster, recently shown to negatively regulate LKB1 upstream of NUAK1 (26), suggestive of feedback regulation (Fig. 3D, E). Similar results were obtained in HCT116 cells (Fig. 3D). Pathway analysis showed broadly similar transcriptional effects of depletion of either NUAK1 or NRF2, while analysis of down-regulated genes revealed significant enrichment for pathways “Oxidative stress” and “NRF2 regulation of oxidative stress” in both instances (Table S1 & S2).

The reduced expression of NRF2 target genes suggested that NUAK1-deficient cells would be hypersensitive to oxidative stress. Accordingly, we detected elevated levels of cytosolic H$_2$O$_2$ in U2OS, multiple CRC cell lines, and VAK colonic spheroids, after acute treatment with HTH-01-015 (Fig. 3F-I), while depletion of NUAK1 sensitized U2OS and multiple CRC cell lines to H$_2$O$_2$-induced cell death, consistent with the inhibitor and RNAi each reducing anti-oxidant buffering capacity, albeit to different degrees (Fig. 3J). Similar sensitization to H$_2$O$_2$-induced cell death was also observed upon CRE-mediated deletion of NUAK1 in MEFs, providing genetic confirmation of the specificity of this effect (Fig. S4D, E). CRC lines with lower levels of NUAK1 were inherently more sensitive to ROS-induced cell death, even in the absence of NUAK1 depletion, compared with cells expressing higher levels of NUAK1, while the relatively modest sensitization of SW480 cells compared with U2OS cells may reflect differences in the efficiency of NUAK1 depletion or indeed the relative expression of NUAK2. Notably, depletion of NUAK1 in some CRC lines resulted in increased NUAK2 expression (Fig. S1L). Importantly, provision of exogenous anti-oxidants significantly rescued human CRC cells (Fig. 3K & S4F) and VAK spheroids (Fig. 3L & S4G) from NUAK1 inhibitor-induced apoptosis, indicating that ROS contributes substantially to cell death in both settings. The remaining levels of cell death measured in the CRC cell lines likely reflects exhaustion of the exogenous anti-oxidant, evidenced by intermediate levels of ROS in cells treated for 8hrs with NUAK1 inhibitor in the presence of Trolox (Fig. S4H, I).
**NUAK1 promotes nuclear translocation of NRF2 by antagonizing GSK3β**

NRF2 was recently described to contain an AMPK-substrate consensus phospho-motif (27) that could potentially be targeted for phosphorylation by NUAK1. We used immunoprecipitation (IP) of Flag-tagged NRF2 followed by immunoblotting with a pan-phospho-AMPK-substrate antibody to assess the influence of NUAK1 inhibition on NRF2 phosphorylation levels but detected no difference (Fig. S5A). Similarly, purified NUAK1 showed no activity towards a corresponding NRF2 peptide *in-vitro* (Fig. S5B). Thus, NRF2 does not appear to be a direct target of NUAK1 kinase activity.

We noticed that acute inhibition of NUAK1 resulted in decreased total NRF2 levels (Fig. 4A). NRF2 is regulated by KEAP1, which sequesters NRF2 in the cytoplasm while targeting it continuously for Ubiquitin-dependent degradation (28, 29). We asked if KEAP1 is required for regulation of NRF2 by NUAK1. As expected, RNAi-mediated depletion of KEAP1 increased basal levels of NRF2, yet concomitant inhibition of NUAK1 continued to reduce total NRF2 protein levels (Fig. 4B). Accordingly, cyclohexamide time-course analysis showed that NUAK1 depletion reduces total NRF2 levels but does not affect the rate of NRF2 degradation, per se (Fig. S5C). KEAP1 contains a number of Cysteine residues that are subject to oxidation and, in the presence of ROS, oxidized KEAP1 releases NRF2 allowing it to translocate to the nucleus and activate transcription (30). We therefore examined NUAK1-depleted or HTH-01-015-treated U2OS cells for nuclear accumulation of NRF2 after acute treatment with H$_2$O$_2$ and found that loss of NUAK1 activity strongly suppressed ROS-induced nuclear accumulation of NRF2 (Fig. 4C). Accordingly, ROS-induced transcription of NRF2 targets was also suppressed upon depletion of NUAK1 (Fig. 4D). Analysis in multiple CRC cell lines likewise revealed that depletion of NUAK1 suppresses ROS-driven NRF2 nuclear accumulation, indicating that this role of NUAK1 is conserved in CRC (Fig. 4E & S5D). Additionally, this role of NUAK1 is at least partially shared with NUAK2, as depletion of
NUAK2 in SW620 cells similarly suppressed peroxide-induced nuclear accumulation of NRF2 (Fig. S5E).

We used unbiased, SILAC-based phospho-proteomics to identify candidate mediators of NRF2 regulation upon acute inhibition of NUAK1 in U2OS cells (see schematic, Fig. S5F). Ser\textsuperscript{445} of MYPT1 was the only site resident within a recognizable AMPK-related kinase consensus motif that was consistently reduced upon NUAK1 inhibition. This analysis also revealed reduced inhibitory phosphorylation of GSK3\textbeta\textsuperscript{9} and a corresponding increase in phosphorylation of multiple GSK3\textbeta targets (Fig. 5A & Table S3). GSK3\textbeta is known to suppress nuclear accumulation of NRF2: In the presence of oxidative stress, activation of AKT inhibits GSK3\textbeta via Ser\textsuperscript{9} phosphorylation, allowing nuclear accumulation of NRF2 (31). We therefore examined the influence of NUAK1 depletion on ROS-driven signal transduction via AKT and GSK3\textbeta. Treatment of U2OS cells with H\textsubscript{2}O\textsubscript{2} rapidly activated AKT, leading to increased GSK3\textbeta\textsuperscript{S9} phosphorylation. Upon depletion of NUAK1, activation of AKT by H\textsubscript{2}O\textsubscript{2} was unimpaired, however, the inhibitory phosphorylation of GSK3\textbeta was strongly reduced, suggesting that NUAK1 may limit de-phosphorylation of GSK3\textbeta\textsuperscript{S9} (Fig. 5B). Similar results were observed upon H\textsubscript{2}O\textsubscript{2} treatment of NUAK1-depleted SW480 cells (Fig. 5C), while treatment with NUAK1 inhibitor suppressed GSK3\textbeta\textsuperscript{S9} phosphorylation in SW480 cells and in VAK LI spheroids (Fig. 5D, E). Notably, phosphorylation of MYPT1 by NUAK1 inhibits PP1\textbeta activity (10) and PP1\textbeta was previously shown to dephosphorylate GSK3\textbeta (32, 33). Strikingly, H\textsubscript{2}O\textsubscript{2} led to a clear increase in NUAK1-dependent MYPT1 phosphorylation (Fig. 5B), suggesting that ROS coordinately activates AKT and inactivates PP1\textbeta (via NUAK1) in order to suppress GSK3\textbeta activity. Significantly, inhibition of GSK3\textbeta stabilized total NRF2 levels and rescued nuclear accumulation of NRF2 in NUAK1-deficient SW480 cells (Fig. 5F & S5G). Interestingly, depletion of PTEN similarly rescued nuclear NRF2, suggesting that the requirement for NUAK1 in this pathway can be overcome by strongly deregulated AKT signaling (Fig. S5H).
Regulation of NUAK1 by ROS and NRF2

We asked if NUAK1 is an integral part of the oxidative stress response pathway. Depletion of NRF2 with 2 independent siRNAs consistently reduced NUAK1 protein levels (Fig. 6A). Examination of the NUAK1 promoter revealed a near-consensus anti-oxidant response element (ARE) located approximately 1.2kb upstream of the NUAK1 transcription start site, and NRF2 chromatin IPs showed specific binding of NRF2 to the putative NUAK1 ARE, albeit at much lower efficiency than to the canonical NRF2 target, HMOX1 (Fig. 6B, C). Treatment of U2OS cells with H$_2$O$_2$ modestly increased NUAK1 mRNA but had much greater influence on NUAK1 protein, suggesting that post-translational regulation may have greater functional impact (Fig. 6D, E). Time-course analysis revealed that H$_2$O$_2$ treatment rapidly increased activating phosphorylation of NUAK1 at Thr211, and consequent MYPT$^{5445}$ phosphorylation, downstream. These changes occur within the same time-frame as increased AKT phosphorylation, known to result from direct inactivation of PTEN by ROS (34), suggesting that ROS may directly modify NUAK1 (Fig. 6F). To investigate this hypothesis, we first used Dimedone labeling (35) of cells expressing FLAG-tagged NUAK1 to measure Cysteine oxidation after H$_2$O$_2$ treatment: Treatment with increasing doses of H$_2$O$_2$ resulted in increased Dimedone labeling of FLAG-immunoprecipitated NUAK1 (Fig. 6G). Consistently, MS analysis of Iodo-acetamide labeling of FLAG-NUAK1 IPs from cells treated for 5 minutes with H$_2$O$_2$ similarly revealed increased oxidation of multiple NUAK1 Cysteines, as compared with untreated controls (Fig. 6H). Collectively, our data suggest a model wherein ROS-dependent activation of NUAK1 coordinates inhibition of PP1β with activation of AKT in order to counteract suppression of nuclear NRF2 by GSK3β (Fig. 6I).

Modeling the therapeutic potential of Nuak1 suppression in vivo

The above data collectively suggest that NUAK1 may be an excellent target for therapeutic intervention in CRC. However, the relatively poor potency of the NUAK1 inhibitors used above
preclude their use in vivo. We therefore employed a doxycycline-inducible RNAi approach to assess the impact of acute Nuak1 suppression on pre-existing tumors. We used Villin-CreER<sup>T2</sup> to limit expression of rtTA<sup>3</sup> to the mouse intestine. Upon activation with doxycycline (Dox), rtTA<sup>3</sup> was then used to drive expression of either of 2 shRNAs, targeting Nuak1 mRNA from nucleotide 612 or 1533 respectively, stringently selected to specifically deplete Nuak1 as previously described (see Supplementary Methods). Figure S6A shows depletion of NUAK1 in MEFs upon Dox-dependent expression of Nuak1 shRNA.

Tumors were initiated in heterozygous floxed Apc (VA) mice by Tamoxifen-dependent activation of CreER<sup>T2</sup>, and tumor development in the colon was accelerated by treatment with dextran sulfate sodium salt (DSS). DSS-treated VA mice develop colonic polyps within 70 days of CreER<sup>T2</sup> activation with >90% penetrance (36), and this time post-induction was chosen to commence Dox-dependent induction of either shRNA. Mice were maintained on Dox for 1 week then harvested for analysis (for a schematic, see Fig. S6B). DSS-treated VA mice lacking either Nuak1 shRNA or rtTA alleles were similarly administered Dox, to control for effects of the antibiotic. Depletion of Nuak1 for just one week strongly reduced the number of tumors per mouse and moreover suppressed the size of the remaining tumors found upon examination (Fig. 7A). Similar results were obtained with both Nuak1 shRNA alleles, strongly suggesting that the observed effects reflect the “on-target” depletion of Nuak1. Of the tumors that persisted in Nuak1 shRNA-expressing mice, all expressed readily detectable levels of Nuak1 mRNA, as measured by ISH (Fig. S6C), indicating that some tumors escape shRNA-mediated Nuak1 depletion. PEARL imaging of intestines of mice injected overnight with Licor ROSstar™ reagent revealed elevated ROS levels in colonic tumors in situ after just 2 days of NUAK1 depletion (Fig. S6D) while IHC analysis showed increased oxidative damage (8-oxo-dG), increased apoptosis (TUNEL), and reduced proliferation (BrdU) in NUAK1-depleted tumors within the same timeframe (Fig. 7B, C). Consistent with our in vitro data, transcriptomic analysis of NUAK1-depleted tumors revealed
significantly reduced expression of a host of NRF2 target genes within 2 days of NUAK1 depletion (Fig. S6E). Importantly, exogenous provision of the antioxidant N-Acetyl-Cysteine (NAC) in drinking water reversed the tumor suppressive effect of *Nuak1* depletion (Fig. 7D & S6F), but had no effect on *Nuak1*-replete tumors (Fig. S6G). We conclude from these results that impairment of cellular anti-oxidant defenses is the underlying mechanism of the tumoricidal effect of *Nuak1* suppression in the gut.

**Discussion**

Here we demonstrate that the AMPK-related kinase NUAK1 plays a key role in protecting colorectal tumors from oxidative stress. Using a combination of genetic and pharmacological approaches, we show that *Nuak1* is required for both formation and maintenance of colorectal tumors after loss of *Apc*; that suppression of NUAK1 reduces viability of transformed intestinal spheroids and of human colorectal cell lines; and that protecting cells from toxic levels of ROS, via facilitation of NRF2-dependent anti-oxidant gene expression, is a key tumor-promoting activity of NUAK1. We show that NUAK1 kinase activity is rapidly increased by ROS following Cysteine oxidation and, moreover, that NUAK1 is transcriptionally regulated by NRF2, placing NUAK1 squarely within the oxidative stress response pathway. Noting that NUAK1 expression is normally highest in highly oxidative tissues (11) it thus appears that protecting cells from oxidative stress is a major physiological role of NUAK1 that has been co-opted by tumor cells to support their survival in the typically harsh tumor microenvironment. AMPK also participates in antioxidant defense albeit indirectly, by conserving NADPH levels via inhibition of lipid biosynthesis (37), and a recent paper has shown a genetic requirement for this activity in MYC-overexpressing melanoma (38). Although AMPK may under certain circumstances directly phosphorylate NRF2 (27), in our system, the observed level of NRF2 phosphorylation is extremely low and is not modulated by
NUAK1 inhibition. As such, AMPK does not presently appear to contribute to regulation of NRF2 by NUAK1.

Instead, we show that NUAK1 facilitates nuclear import of NRF2 by counteracting negative regulation of this process by GSK3β, and that direct inhibition of GSK3β restores NRF2 nuclear import in NUAK1-deficient cells. ROS inactivation of PTEN activates AKT, resulting in direct inhibitory phosphorylation of GSK3β on Ser9 (31, 39). This phosphorylation is opposed by PP1β, which reactivates GSK3β (33). We show that activation of AKT by ROS is unaffected by NUAK1 suppression, however, AKT-dependent regulation of GSK3β is facilitated by inhibition of PP1β by NUAK1 via phosphorylation of the PP1β regulatory subunit MYPT1. NUAK1 is thus required to coordinate inhibition of PP1β with AKT activation in response to ROS, thereby allowing GSK3β to be switched off long enough to permit NRF2 nuclear accumulation, providing fascinating new insight into temporal coordination of Redox signal transduction. This role of NUAK1 is likely to be shared with NUAK2, which similarly suppresses PP1β via MYPT1, and indeed, we show that depletion of NUAK2 similarly reduces nuclear NRF2 in cells that highly express NUAK2. However, further work is needed to distinguish between specific effects of NUAK1 and NUAK2 on PP1β and beyond.

This mechanism of regulation suggests that the effects of NUAK1 suppression may be quite pleiotropic and indeed, our phosphor-proteomic analysis indicated modulation of multiple GSK3β targets in addition to NRF2. Moreover, transcriptional regulation by NRF2 reaches far beyond anti-oxidant gene expression, as previously noted (25). However, the central role of NRF2-dependent anti-oxidant gene expression in supporting tumor cell viability is attested to 1) by the hypersensitivity of NUAK1-depleted CRC tumor lines to oxidative stress-induced apoptosis and 2) by the dramatic rescue of NUAK1-depleted colonic tumors and inhibitor-treated spheroids upon provision of exogenous anti-oxidants. The more modest (but nonetheless significant) anti-oxidant rescue observed in HTH-01-015-treated CRC cells likely reflect the limits of trying to buffer against
oxidative stress in standard cell culture (40). Although attempts to recapitulate the cytotoxic effects of NUAK1 inhibition in CRC cells using RNAi were unsuccessful, we believe that the effects of HTH-01-015 are specific for NUAK1 for several reasons: 1) This compound has been tested against over 120 kinases and is extremely selective for NUAK1, although at higher concentrations it does show some activity towards NUAK2 and possibly MARK3 (23); 2) Cytotoxicity was only observed at concentrations that yielded a clear reduction in MYPT1 phosphorylation, thus indicating greater suppression of either NUAK1 or a NUAK1-like activity; 3) cytotoxicity was reproducible with the unrelated compound WZ4003; 4) consistent with our previous demonstration of a synthetic lethal relationship between MYC & NUAK1 (9), sensitivity to HTH-01-015 was MYC-dependent and CRC cell death was rescued by MYC depletion. It is thus unclear why cytotoxicity was not observed using RNAi in the cell culture setting, except in instances of simultaneous peroxide challenge. It maybe that very low levels of residual NUAK1 suffice to suppress cell death, consistent with our data in SW620 cells, which do express very low levels of NUAK1. Additionally, the asynchronous nature of RNAi may allow cultured cell populations time to quench H₂O₂ before the threshold for loss of viability is breached and, accordingly, depletion of NUAK1 resulted in upregulation of NUAK2 in multiple CRC lines, likely dampening the impact of NUAK1 depletion. Furthermore, HTH-01-015 has been shown to partially inhibit NUAK2 at the 10µM dose that exhibited cytotoxicity in CRC lines (23) and, while we cannot entirely exclude the possibility of an off-target effect of the inhibitor, the fact that CRC cytotoxicity at this dose was significantly rescued by both anti-oxidant provision and by depletion of c-MYC strongly supports our interpretation that the on-target effect of the inhibitor is responsible for induction of tumor cell death. The differential sensitivity of some cells (eg. SW480) to the NUAK1 inhibitor versus peroxide challenge after NUAK1 depletion by RNAi may thus reflect expression of NUAK2 and/or the continued biochemical activity of residual levels of NUAK1 after RNAi-mediated depletion.
Our previous work linked the selective requirement of tumor cells for NUAK1 to MYC overexpression, and this link is borne out here by the rescue of NUAK1 inhibitor-induced death upon depletion of MYC from CRC cell lines. In the intestine, loss of Apc leads to β-Catenin-dependent overexpression of endogenous Myc. Although deregulated Myc is alone insufficient for intestinal tumor formation (41), it is nonetheless required for β-Catenin-driven polyposis and, significantly, is also required for the elevation of ROS levels observed in vivo upon loss of Apc (42). Colorectal tumors will thus have evolved in the face of continuous oxidative stress and cells derived therefrom would likely be better buffered against oxidative stress than cells (eg. U2OS) that lack MYC deregulation. Accordingly we show that U2OS cells depleted of NUAK1 are exquisitely sensitive to a peroxide challenge and that this is phenocopied by MYC overexpression. Note that the absence of NUAK2 expression from U2OS cells likely increases their reliance upon NUAK1. NUAK1 thus functions in 2 major tumor-protective pathways, ATP homeostasis and the oxidative stress response, that are rapidly engaged to support viability upon MYC overexpression (43). As such, NUAK1 appears to be more intimately linked with the downstream metabolic consequences of MYC deregulation than with the absolute levels of MYC protein per se and we recently linked MYC deregulation to Calcium-dependent activation of NUAK1 in LKB1 deficient cells (13).

Exploiting the heightened sensitivity of tumor cells to ROS is emerging as a plausible strategy for cancer therapy (44, 45). Recently, intravenous injection of very high doses of di-hydro-Ascorbate was shown to suppress colorectal tumor formation by saturating ROS scavengers, and subsequent work suggests that this strategy may indeed show clinical benefit (46, 47). With increasing evidence linking elevated NRF2 to aggressive disease (48, 49), disabling anti-oxidant defenses via transient inhibition of NUAK1 may offer a new strategy for improving therapeutic outcomes in cancer.
**Materials & Methods**

**Mouse experiments and analyses**

All experiments involving mice were approved by the local ethics committee and conducted in accordance with UK Home Office license numbers 70/7950 & 70/8646. Mice were housed in a constant 12hr light/dark cycle, and fed and watered ad libitum. Mice bearing doxycycline-inducible shRNAs targeting NUAK1 are described in the supplementary materials section. All mice were maintained on mixed (FVBN x C57Bl/6 x 129/SV) background and littermate controls were used for all experiments. To induce allele recombination, transient activation of CreER\textsuperscript{T2} in the intestine was performed on mice aged 6-12 weeks via single IP injection of 50mg/kg Tamoxifen. For survival analysis, humane end points were defined as exhibition of 2 or more symptoms: >15% weight loss; pale feet; lethargy; bloody stool. Where indicated, 1.75% dextran sodium sulfate (DSS), m.w. 35k-50kDa (M.P. Biochemicals) was administered in drinking water for 5 days, commencing 4 days post allele induction, followed by distilled water for 1 week, then tap water. Doxycycline (Sigma; in H\textsubscript{2}O) was administered by oral gavage in 2mg daily boluses, from day 64 to day 70 post-induction. N-Acetyl-Cysteine (Sigma; 4% w/v soln.) was administered in drinking water, starting 3 days before shRNA induction, and replaced every 3-4 days until sacrifice. All mice were sacrificed using a schedule 1 procedure. ROSstar 650 reagent (Licor) was injected IP the day before tissue harvesting and signal was detected by PEARl imaging.

**Crypt culture**

Primary spheroid cultures of intestinal crypts were established as previously described (50) from the SI and Colon of VA\textsuperscript{Hom}K and VA\textsuperscript{Hom}KN mice: Adult mice were induced as above and tissues harvested 4 days later. Intestines were flushed with ice-cold PBS and opened longitudinally and villi were removed using a glass coverslip. Intestines were incubated in EDTA/PBS (2mM for SI; 25mM for LI) for 30min at 4\textdegree C. Excess solution was discarded and loose intestine fragments were
collected by manual trituration in 3 PBS washes. The crypt-enriched fractions were passed through a 70μM cell strainer and pelleted at 600rpm for 2min in a table-top centrifuge. Resuspended crypts were counted by hemocytometer, then seeded in Matrigel (BD Bioscience) with Advanced DMEM/F12 media (Invitrogen), supplemented with 10mM HEPES; 2mM Glutamine; 0.1% FBS; Pen/Strep, N-2 & B-27 supplements (1X, Invitrogen). Alternatively, for quantification of primary spheroid formation, isolated crypts were further incubated in Cell Dissociation solution (Thermo) until a single cell suspension was achieved. Cells were then counted and seeded at normalized density as above. Growth factors Noggin (100ng/ml) and EGF (50ng/ml; Peprotech) were added to primary cultures but removed from subsequent passages. Spheroids were counted manually 3 or 4 days after seeding. Wild-type organoid cultures were prepared similarly but additionally supplemented with R-Spondin (500ng/ml; R&D systems). Established crypt cultures were split 1-2 times per week by manual disruption followed by incubation in Cell Dissociation solution (Thermo) until a single cell suspension was achieved. Cells were then counted and re-seeded at normalized density. NUAK1 inhibitors, HTH-01-015 (Apex Biotech) or WZ4003 (Medchem Express) in DMSO, were added to single cell suspensions at the indicated concentrations. Trolox [(±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid] (Sigma) was added to single cell suspensions at a final concentration of 500μM for 16hrs prior to HTH-01-015 and replenished daily for 3 days. ROS detection was performed by confocal fluorescent microscopy using 5μM CellRox green (Thermo; 3hrs @ 37C) after overnight treatment of pre-formed spheroids with HTH-01-015.

Cell Lines

U2OS (2009), HCT116, SW620 & SW480 (all in 2013) cell lines were obtained from the ATCC and cultured in DMEM supplemented with Penn/Strep & 10% FBS. Cells were expanded initially upon receipt and aliquoted into frozen stocks. Upon resuscitation, cells were passaged as required and
discarded after no more than 3 months of continuous culture. Cell lines were periodically validated using the Promega Geneprint 10 authentication kit, most recently in August 2017. All cell lines in culture were tested every 3 months for mycoplasma.

**Transcriptomic Analysis**

Whole-transcriptome analysis was performed by Illumina RNA-Sequencing. The following datasets are available through ArrayExpress: U2OS +/- NUAK1 shRNA, accession number E-MTAB-6244; SW480 +/- siNRF2 or siNUAK1, accession number E-MTAB-6264; Apc/DSS-induced colonic tumors +/- shNUAK1, accession number E-MTAB-6265. A full description of methodology is provided in the Supplementary Material.

**Statistical Analysis**

All experiments were performed at least 3 times except where noted in the text. Raw data obtained from quantitative Real Time PCR, FACS and spheroid generation assays were copied into Excel (Microsoft) or Prism (Graphpad) spreadsheets. All Mean & SEM values of biological replicates were calculated using the calculator function. Graphical representation of such data was also produced in Excel or in Prism. Box & spider plots were generated using Prism. Statistical significance for pairwise data was determined by the Student’s (Unpaired) or Paired T test, as indicated. For multiple comparisons, ANOVA was used with a post-hoc Tukey test. * denotes P<0.05; ** denotes P<0.01; *** denotes P<0.001. For Kaplan-Meier plots, Mantel Cox logrank P values are presented; for tumor enumeration, Mann Whitney tests were performed.

Additional methods are described in the Supplementary Materials
Acknowledgements

The authors wish to thank the staff of the CRUK Beatson Institute Biological Services Unit for animal husbandry and assistance with in vivo experiments; the staff of the CRUK BI Histology core facility and William Clark of the NGS core facility; David McGarry, Rene Jackstadt, Jiska Van der Reest, Justin Bower and Heather McKinnon for many helpful discussions, and countless colleagues at the CRUK BI and Glasgow Institute of Cancer Sciences for support; Prem Premsrirut & Mirimus Inc. for design and generation of dox-inducible Nuak1 shRNA expressing mice; Nathanael Gray for initial provision of NUAK1 inhibitors. Funding was provided by the University of Glasgow and the CRUK Beaton Institute. J.P. was supported by European Commission Marie Curie actions C.I.G. 618448 “SERPLUC” to D.J.M.; N.M. was supported through Worldwide Cancer (formerly AICR) grant 15-0279 to O.J.S. & D.J.M.; B.K. was funded through EC Marie Curie actions mobility award 705190 “NuSiCC”; T.M. was funded through British Lung Foundation grant APHD13-5. The laboratories of S.R.Z. (A12935), O.J.S. (A21139) and M.D. (A17096) are funded by Cancer Research UK. O.J.S. was additionally supported by European Research Council grant 311301 “ColoCan”.
References


Figure Legends

Figure 1: NUAK1 overexpression correlates with tumor progression, lymph node infiltrates, and reduced OS in human CRC

A) Summary of NUAK1 mRNA detection in a human CRC TMA (N=660), sorted by Dukes’ grade A-C; N=normal colon. Asterisks indicate significance (1-way ANOVA & post-hoc Tukey test). B) Box and whisker plots of median-centered NUAK1 mRNA expression from the TCGA colorectal adenocarcinoma cohort accessed via Oncomine: Left panel shows early (T1,2) versus late (T3, 4) stage CRC; right panel shows tumors with (N1,2) or without (N0 lymph node metastasis. C) Overall survival of human CRC patients (N=947) separated by high versus low NUAK1 expression. Logrank P value, hazard ratio (HR) and 95% confidence interval (CI) shown. D) Box & whisker plots of NUAK1 mRNA levels in human CRC separated by risk group as per (C). T-test P value shown. (C&D) Data were mined and graphs adapted from Metabase SurvExpress. E) Apoptosis induced in human CRC cell lines 48hrs after treatment with the indicated concentrations of HTH-01-015. Red bars indicate AnnexinV/Propidium Iodide (AV/PI) double positive cells; black bars indicate AnnexinV positive cells. Mean and SEM of 3 independent experiments shown; asterisks show significance (ANOVA & post-hoc Tukey test, relative to vehicle treated controls (-)). F) Immunoblots of lysates from human CRC cell lines show reduction in MYPT1 Ser445 phosphorylation upon inhibition of NUAK1 (8hr). The asterisk indicates a non-specific band. G) Apoptosis induced in U2OS cells 48hrs after treatment with 10µM HTH-01-015 or WZ4003. Mean and SEM of 3 independent experiments shown; asterisks show significance (ANOVA & post-hoc Tukey test, relative to vc controls). Ns = not significantly increased relative to untreated controls. Immunoblot (lower panel) shows suppression of p-MYPT1S445 upon NUAK1 inhibition. H) Apoptosis induced in U2OS-MycER cells upon NUAK1 inhibition in the presence (+ OHT) or absence (- OHT) of 4-hydroxy-tamoxifen-dependent activation of overexpressed MycER. Mean and SEM of 3 independent experiments shown; asterisks denote significance (2-way ANOVA & post-hoc Tukey
test). Immunoblot shows nuclear stabilization of MycER by 4-OHT. I) Rescue of CRC cells from HTH-01-015-induced apoptosis upon depletion of MYC. Mean and SEM of a representative experiment (N≥2) in each cell line shown; asterisks denote significance (ANOVA & post-hoc Tukey test. Immunoblots show depletion of MYC in the same cell lines (lower panels).
**Figure 2: Deletion of Nuak1 suppresses colorectal tumor formation**

**A**) Number of large intestine (LI) tumors per mouse in VAK (N=12) and VAKN (N=16) mice, harvested at end-point. Black bar indicates Mean tumor number while red bars indicate SEM.  **B**) Total tumor burden (area) per mouse of the indicated genotypes. Mean & SEM shown.  **C**) Size of individual tumors in mice of the indicated genotypes. Box plots depict the median (red bar) and interquartile range of individual tumor area; whiskers reflect maximum observed tumor size. N=192 (VAK) & 119 (VAKN). (A-C) P values from Mann-Whitney test shown. **D**) Representative H&E stained images of tumors from VAK (top panels) and VAKN (lower panels) mice. Panels i-iii: scale bar =500μm. Panel iv: zoom of inset from iii, scale bar =200μm, T=tumor, N=normal tissue. **E**) Number of spheroids arising from freshly isolated VA\textsuperscript{Hom}KN small and large intestine, normalized to VA\textsuperscript{Hom}K controls seeded on the same day. Mean and SEM from VA\textsuperscript{Hom}K (N=4) and VA\textsuperscript{Hom}KN (N=6) mice shown. *** denotes significance (Unpaired T-test). **F**) Representative images of spheroids from (E). Scale bar =500μm.  **G**) Detection of Nuak1 mRNA in colonic spheroids from VA\textsuperscript{Hom}KN mice relative to Nuak1 transcript levels in VAK spheroids. Mean of 4 VA\textsuperscript{Hom}K and 6 VA\textsuperscript{Hom}KN mice shown. Error bar indicates SEM.  **H**) Numbers of VA\textsuperscript{Hom}K small intestine-derived spheroids after treatment with Nuak1 inhibitors HTH-01-015 (HTH) or WZ4003 (WZ), normalized to vehicle treated control (vc). Mean & SEM of 3 independent experiments shown; asterisks show significance (1-way ANOVA & post-hoc Tukey test, relative to vc controls).  **I**) Numbers of VA\textsuperscript{Hom}K large intestine-derived spheroids treated and graphed as per (H).
Figure 3: NUAK1 promotes NRF2-dependent gene expression

A) Top 10 pathways modulated in U2OS cells after depletion of NUAK1 by shRNA, identified by Metacore GeneGO analysis of RNA-Seq data. FDR = False discovery rate. B) RNA-Seq read counts of select NRF2 targets from (A). Mean & SEM of 3 biological replicates shown; asterisks denote significance (unpaired T-test). C) Reduction of NRF2 target gene expression upon inhibition of NUAK1 for 8hrs in U2OS cells. Mean & SEM of 3 independent experiments shown; asterisks denote significance (1-tailed T test). D) Comparison of selected NRF2 target gene expression upon depletion of NRF2 versus depletion of NUAK1 in CRC cell lines, HCT116 and SW480. N=4. Mean & SEM shown; asterisks denote significance (Unpaired T-test). E) Global analysis of the transcriptomic impact of NRF2 depletion versus NUAK1 depletion in SW480 cells. F) FACS detection of cytosolic ROS levels by CellRox Deep Red™ staining of U2OS cells upon acute inhibition of NUAK1. The upper panel shows a representative FACS graph; the lower panel shows Mean ± SEM fluorescence intensity of HTH-treated relative to vehicle treated control cells from 3 independent experiments. G) CellRox detection of ROS levels in human CRC lines, as per (F), upon acute inhibition of NUAK1. Mean ± SEM from 3 independent experiments shown; asterisks denote significance (1-tailed T-test) H) Representative image showing CellRox staining of VAK spheroids after treatment with HTH-01-015. I) quantification of spheroid fluorescence from (H) using ImageJ. N=41 per group. J) Apoptosis induced by treatment of U2OS (500µM) or CRC cells (1mM) with H2O2, with and without prior depletion of NUAK1, measured at 24hrs. Mean & SEM of 3 biological replicates from at least 2 independent experiments for each cell line shown. Asterisks denote significance (unpaired T-test). K) Provision of exogenous antioxidant Trolox attenuates HTH-01-015-induced killing in human CRC lines. Mean & SEM of 3 independent experiments shown. Asterisks denote significance (2-way ANOVA & post-hoc Tukey test). L) Representative images showing Trolox rescues growth of Colonic VA^Hom^K spheroids from Nuak1 inhibition (3 days). Scale bar =100µm. Right panel shows quantification of spheroids after NUAK1 inhibition in
the presence and absence of Trolox (500 µM). Mean and SEM of 3 independent experiments, normalized to vehicle treated controls are shown. Asterisks denote significance (2-way ANOVA & post-hoc Tukey test).
**Figure 4: NUAK1 promotes nuclear accumulation of NRF2**

A) NRF2 immunoblot of U2OS whole cell extracts harvested after 4 or 8hrs NUAK1 inhibition. Reduced phospo-MYPT1 confirms NUAK1 inhibition. The lower panel shows densitometry of the NRF2 blot shown.  

B) NRF2 immunoblot of KEAP1 depleted U2OS cells upon NUAK1 inhibition for 8hrs. The lower panel shows densitometry of the NRF2 blot shown. The right panel confirms KEAP1 depletion with 2 independent siRNAs.  

C) Immunoblots of NRF2 protein levels in nuclear extracts from U2OS cells after acute (30mins) treatment of cells with 500μM H$_2$O$_2$, with and without prior depletion of NUAK1 by 2 distinct siRNAs (left & center panels), or upon NUAK1 inhibition by HTH-01-015 (10μM). All blots (A-C) are representative of at least 3 independent experiments.  

D) Expression analysis of NRF2 target genes GCLC and GCLM shows suppression of H$_2$O$_2$-induced mRNA levels upon depletion of NUAK1. Mean and SEM of 3 independent experiments, normalized to pre-peroxide treatment, are shown. Asterisks denote significance (2-way ANOVA & post-hoc Tukey test).  

E) Suppression of ROS-induced NRF2 nuclear translocation in multiple human CRC cell lines upon depletion of NUAK1.
**Figure 5: NUAK1 inhibits negative regulation of NRF2 by GSK3β**

**A)** Summary of phospho-proteomic changes induced in U2OS cells upon treatment with 10µM HTH-01-015 for 1hr. Left panel depicts the comparison of “forward” (X-axis) with “reverse” (Y-axis) SILAC labeled cells. Phosphorylation sites in the lower left quadrant thus show consistent reduction in levels while those in the upper right quadrant show consistently higher phosphorylation levels detected by mass spectrometry. The previously validated NUAK1 substrate MYPT1 was used to set a threshold for acceptance/rejection of modulated phosphor-peptides. Right panel shows zoom of the inset from left panel, with known (red) and predicted (orange) GSK3β substrates highlighted. **B)** Immunoblots of lysates from NUAK1-depleted or control U2OS cells after treatment with H₂O₂ (500µM) showing effects on AKT, GSK3β and MYPT1 phosphorylation. The lower panel shows the ratio of Ser9-phospho-/total GSK3β, measured by Image-J analysis of the presented immunoblots. **C)** Immunoblots of NUAK1-depleted or control SW480 cytosolic fractions after treatment with H₂O₂ (30 minutes). The lower panel shows the ratio of Ser9-phospho-/total GSK3β, measured by Image-J analysis of the presented immunoblots. **D)** Immunoblots show reduced Ser9-phosphorylation of GSK3β in the presence of NUAK1 inhibitors. The lower panel shows the ratio of Ser9-phospho-/total GSK3β, measured by Image-J analysis of the presented immunoblots. **E)** Immunoblots show suppression of nuclear NRF2 and Ser9-phosphorylation of GSK3β upon inhibition of NUAK1 (5µM HTH-01-015 for 16hrs) in VAK large intestine-derived spheroids. Note that the presence of Matrigel likely blunts the impact of treatment with exogenous H₂O₂ (2mM for 1hr). The lower panel shows quantification of nuclear NRF2 levels by Image-J analysis. **F)** Pre-treatment of NUAK1 depleted SW480 cells with GSK3β inhibitors BIO-acetoxime (a; 1µM for 6hrs) or CHIR99021 (b; 3µM for 6hrs) restores ROS-induced NRF2 nuclear translocation. All images are representative of at least 3 independent experiments.
Figure 6: Regulation of NUAK1 by NRF2 and ROS

A) Immunoblots show reduced NUAK1 protein and reduced MYPT1$_{S445}$-phosphorylation in U2OS cells upon depletion of NRF2 using 2 distinct siRNAs. B) Alignment of a putative anti-oxidant response element (ARE) in the NUAK1 promoter with the NRF2-binding consensus sequence. C) Chromatin IP of NRF2-bound DNA probed with primer pairs flanking (F1/R1; F2/R2) or distal to (F3/R3) the putative ARE in the NUAK1 promoter (see diagram). The right panel shows NRF2 binding to the canonical target gene HMOX1 from the same analysis. Mean & SEM of technical replicates from 1 of 2 independent experiments shown. D) QPCR measurement of NUAK1 mRNA in U2OS cells treated with/without H$_2$O$_2$ (100µM) for 4hrs. Mean & SEM of 3 experiments. * denotes significance (paired T-test). E) Immunoblot of NUAK1 protein levels after treatment of U2OS cells (1hr) with the indicated concentrations of H$_2$O$_2$. F) Immunoblots of T211 NUAK1 and S445 MYPT1 phosphorylation upon acute treatment of U2OS (left panels) or SW480 (right panels) with H$_2$O$_2$ for the indicated times. G) Oxidation of NUAK1 protein detected by Dimedone labeling of U2OS cells expressing FLAG-tagged NUAK1 and treated for 5 minutes with 500mM H$_2$O$_2$. H) Identification of oxidized Cysteines in FLAG-tagged NUAK1 by MS analysis of Iodoacetamide labeling of U2OS-FLAG-NUAK1 cells treated with/without H$_2$O$_2$ for 5 minutes. Lysates were labeled with heavy ($^{13}$C) or light ($^{12}$C) Iodoacetamide, followed by immunoprecipitation of FLAG-NUAK1. Plot shows analysis of reciprocally labeled samples from 2 independent experiments. Mean and SD indicated. I) Model integrating NUAK1 suppression of PP1β-dependent de-phosphorylation of GSK3β as an integral step in nuclear mobilization of NRF2 in response to oxidative stress.
Figure 7: Acute depletion of NUAK1 reverses colorectal tumors via increased ROS

A) Colonic tumor number per mouse (left panel), total tumor burden (center panel) and individual tumor size (right panel), in DSS-treated VA mice after 7 days of Nuak1 depletion in the gut using either of 2 doxycycline-inducible shRNAs (1533, N=10; or 612, N=7), compared with doxycycline treated controls lacking either shRNA or the rtTA3 allele (-, N=7). Graphs depict Mean (blue lines) and SEM (red bars). Red asterisks indicate significance, relative to untreated controls (1-way ANOVA & post-hoc Tukey test). An outlier mouse in the shNuak-612 cohort is circled (center panel) and all tumors present within the LI of that mouse are labeled in blue (right panel). The outlier and corresponding tumors were included in the statistical analysis. Total tumor burden is significantly reduce by shNUAK1-612 if the outlier is omitted. B) Representative IHC analysis of proliferation (BrdU), apoptosis (TUNEL) and oxidative damage (nuclear 8-Oxo-deoxyGuanine) with corresponding ISH analysis of NUAK1 mRNA (red dots) in selected tumors from control (top panels) and shNUAK1-1533 mice treated for 2 days with doxycycline. C) HALO automated quantification of BrdU, TUNEL & 8-Oxo-Guanine IHC in individual tumors from shNUAK1 expressing (N=6) or control (N=6) mice, as per (B). Mean (blue bars) and SEM (red bars) indicated. Red asterisks indicate significance (Mann Whitney Test). D) Tumor number, total tumor burden and individual tumor size in DSS-treated VA mice after 7 days of Nuak1 depletion in the gut using shNuak-1533, in mice given N-Acetyl-Cysteine (NAC, N=8) compared with no exogenous antioxidant (nt). Note that the NAC-untreated data are the same used in (A). Red asterisks indicate significance (Mann Whitney Test).
Figure 3

A

<table>
<thead>
<tr>
<th>Rank</th>
<th>Regulated Pathway</th>
<th>P-Value</th>
<th>FDR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>SREBP Transcriptional control of Cholesterol &amp; FA synthesis</td>
<td>1.89e-13</td>
<td>1.15e-10</td>
</tr>
<tr>
<td>2</td>
<td>Cell Adhesion, ECM Remodeling</td>
<td>1.25e-12</td>
<td>3.81e-10</td>
</tr>
<tr>
<td>3</td>
<td>Development, Role of IL8 in Angiogenesis</td>
<td>6.74e-8</td>
<td>1.37e-5</td>
</tr>
<tr>
<td>4</td>
<td>Oxidative stress, Role of Sirtuin1 and PGC1a</td>
<td>3.15e-7</td>
<td>4.81e-5</td>
</tr>
<tr>
<td>5</td>
<td>Cell Adhesion, Chemokines &amp; Adhesion</td>
<td>8.34e-7</td>
<td>1.01e-4</td>
</tr>
<tr>
<td>6</td>
<td>NRF2 regulation of Oxidative Stress response</td>
<td>1.25e-6</td>
<td>1.27e-4</td>
</tr>
<tr>
<td>7</td>
<td>Regulation of Lipid Metabolism</td>
<td>9.92e-6</td>
<td>8.65e-4</td>
</tr>
<tr>
<td>8</td>
<td>Glutathione Metabolism</td>
<td>4.41e-5</td>
<td>3.35e-3</td>
</tr>
<tr>
<td>9</td>
<td>Glutathione Metabolism, human version</td>
<td>4.94e-5</td>
<td>3.35e-3</td>
</tr>
<tr>
<td>10</td>
<td>Cell Adhesion, Plasmin Signaling</td>
<td>6.72e-5</td>
<td>4.10e-3</td>
</tr>
</tbody>
</table>

B

NRF2-dependent gene expression

C

NRF2-dependent gene expression

D

<table>
<thead>
<tr>
<th>Pathway</th>
<th>HCT116</th>
<th>SW480</th>
</tr>
</thead>
<tbody>
<tr>
<td>GCLC</td>
<td></td>
<td>**</td>
</tr>
<tr>
<td>GCLM</td>
<td>**</td>
<td></td>
</tr>
<tr>
<td>GSHR</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>MGST</td>
<td></td>
<td>***</td>
</tr>
<tr>
<td>TXN</td>
<td></td>
<td>***</td>
</tr>
</tbody>
</table>

E

SW480 significantly regulated genes

F

U2OS

G

SW620

H

VAK Spheroids

I

Rel. fluorescence a.u.

J

U2OS

SW480

K

SW620

SW480

L

VAK Colonic Spheroids
Figure 4

A

4 hrs 8 hrs

<table>
<thead>
<tr>
<th>mM HTH</th>
<th>NRF2</th>
<th>pMYPT1</th>
<th>MYPT1</th>
<th>β-Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.5</td>
<td>1.5</td>
<td>2.5</td>
<td>2.1</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Relative NRF2 expression

B

nt siRNA  Keap1 si1  Keap1 si2  Si Keap1

<table>
<thead>
<tr>
<th>μM HTH</th>
<th>Nrf2</th>
<th>β-Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.7</td>
<td>1.5</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

H2O2 -- ++
siRNA nt

mRNA rel. to ctrl

D

GCLC  GCLM

H2O2

siRNA nt Nuak1 nt Nuak1

mRNA rel. to ctrl

*  **  ns

E

SW480  HCT116

- + - + - + - + - +

LS174T  SW620

- + - + - + - + - +

Nrf2  Lamin A/C

- + - + - + - + - +

siCon siNUAK1  siCon siNUAK1

H2O2
Figure 5

A

HDH/Ctl Rev (log2)

HDH/Ctl Fw (log2)

-4 -3 -2 -1 -0.5 0 0.5 1 1.5 2

-4 -3 -2 -1 0 1 2

Increased by HTH

Decreased by HTH

B

Scr  siNUAK1

0 10 30 0 10 30 min. H2O2

pAKT S473

AKT

pGSK3β S9

GSK3β

NUAK1

pMYPT1 S445

Actin

p-Ser9/total GSK3β

relative levels a.u.

si Con NUAK1

0 10 30 0 10 30 min. H2O2

C

siCon siNUAK1

- + - + H2O2

pAKT S473

AKT

pGSK3β S9

GSK3β

NUAK1

pMYPT1 S445

Actin

p-Ser9/total GSK3β

relative levels a.u.

D

HTH-5μM WZ-5μM

H2O2

- + - + H2O2

- + - + H2O2

pGSK3β S9

GSK3β

Actin

E

VAK LI spheroids

HTH-5μM H2O2

- + - + H2O2

Nrf2

Lamin A/C

pGsk3β S9

Gsk3β

β− Actin

F

GSK3i-a GSK3i-b GSK3i-a GSK3i-b

- + - + H2O2

Nrf2

Nuak1

Lamin

Scr siNUAK1

- + - + H2O2

Nrf2/Lamin A/C

relative levels a.u. - + - + H2O2

HTH
Figure 7

A

Vil-CreERT²;Apc⁺⁻/+ + DSS + 1wk Doxycycline

No. of Li Tumors

Total Tumor Burden

Indiv. Tumor Size

B

H&E  Nuak1 ISH  BrdU  TUNEL  8-Oxo-dG

Control

shNuak1 1533 Tumour 1

shNuak1 1533 Tumour 2

C

BrdU  TUNEL  8-Oxo-dG

% of tumor cells

D

Vil-CreERT²;Apc⁺⁻/+DI-shNuak1¹⁵³³ + DSS + 1wk Doxycycline

No. of Li Tumors

Total Tumor Burden

Indiv. Tumor Size
Supplementary Materials Index

Figures & Legends:
Figure S1, panels a-p (2 pages)
Figure S2, panels a-g (3 pages)
Figure S3, panels a-e (1 page)
Figure S4, panels a-i (1 page)
Figure S5, panels a-h (1 page)
Figure S6, panels a-g (3 pages)

Tables & Legends:
Table S1 (1 page)
Table S2 (1 page)
Table S3 (Excel spreadsheet – provided separately)

Detailed Materials & Methods

Supplementary References
Supplementary Materials & Methods

Mice & procedures
The Villin-CreER\textsuperscript{2} (51); Floxed Apc (52); LSL-Kras\textsuperscript{G12D} (53), floxed Nuak1 (11) & Rosa26-CAAGS-rtTA3 (54) allelic mice were described previously. Mice bearing the doxycycline-inducible shRNA alleles targeting Nuak1 were generated by Mirimus Inc., as described previously (55). Briefly, shRNA candidates were selected using the sensor assay (56). Two shRNAs were chosen that scored >5 and produced knockdown >90%. The selected shRNA sequences were subsequently cloned in the miR-E backbone (57) within the 3'UTR of a turboGFP cDNA downstream of a TRE in the Col1a1 TgGM vector and targeted to the Col1a1 locus using standard protocols (54). Targeted ES cells were injected using blastocyst injection technique. Resulting shRNA mice were of mixed C57BL/6 x 129/SV background.

For tumor enumeration, small intestines and colons were flushed with PBS, mounted ‘en face’ and fixed overnight in formalin. Tumor area was measured as width by length, omitting depth as negligible/immeasurable in many instances. For histological examination, fixed tissue was then rolled (‘swiss roll method’) and embedded in paraffin for sectioning, followed by standard staining in hematoxylin and eosin (H&E). Additionally, prior to fixation and immediately upon harvest, a small number of representative tumors and adjacent normal tissue were dissected and flash-frozen for RNA analysis. For immunohistochemistry, FFPE tissue sections were deparaffinized in 3 changes of xylene and rehydrated in graded ethanol solutions. Antigen retrieval was performed by microwaving in 10mM Sodium Citrate, pH6.0.

Endogenous peroxidases were quenched in 3% H\textsubscript{2}O\textsubscript{2} and non-specific binding was blocked with 1 or 3% BSA solution. The following antibodies were used: Ki67 (Thermo Fisher, RM-9106-50); Cleaved Caspase 3 (Cell Signaling, 9661); Lysozyme (Dako, A099); BrdU (Beckton Dickinson, BD347580); 8-Oxo-dG (Abcam, AB48508). Goblet cells were stained with Periodic acid Schiff (PAS). TUNEL staining was performed using ApopTag peroxidase kits (Millipore). For quantification of IHC, 3-5 20X fields were scored on representative sections from at least 3 mice of each genotype. In situ hybridization (RNA-Scope) was performed according to the manufacturers directions (Advanced Cell Diagnostics; ACD): 4μm FFPE tissue sections were baked at 60°C for 1hr, then de-paraffinized and rehydrated. Endogenous peroxidases were blocked in H\textsubscript{2}O\textsubscript{2} followed by antigen retrieval (100°C for 8 min.) and protease digestion (H\textsubscript{2}O\textsubscript{2} & Protease Plus kit, ACD). For in-situ hybridization, sections were hybridized with ACD-designed probes for Nuak1 (434281), positive ctrl PP1β (313911) or negative ctrl DapB (322330) for 2hrs at 40°C. Probe detection was performed using RNA-Scope kit reagents (ACD 322310) and counterstained with Hematoxylin.

Cell culture & analysis
U2OS, HCT-116; SW620; LS174T and SW480 cells were obtained from the ATCC and maintained in DMEM (25mM Glucose) with Penn/Strep and 10% FBS. All cell lines were validated using an approved in-house validation service (CRUK-BICR) and tested periodically for mycoplasma. Primary mouse embryo fibroblasts (MEFs) were generated as previously described (58) by interbreeding heterozygous floxed Nuak1 mice, generating homozygous Nuak1\textsuperscript{FL/FL} and Nuak1\textsuperscript{1/-} MEFs, and maintained as above. To delete floxed Nuak1, MEFs were infected overnight with 300pfu/cell Adeno-CRE (Uni. Iowa). Alternatively, MEFs were infected with retrovirus expressing CreER\textsuperscript{2}, selected on Puromycin for 48hrs, and CreER\textsuperscript{2} was subsequently activated by treatment with 100nM 4-OHT. Cells in log phase growth were treated with the indicated concentrations of Nuak1 inhibitors (HTH-01-015 and WZ4003). Where indicated, cells were pre-incubated with 500μM of Trolox for 8hrs prior to treatment with Nuak1 inhibitor. Equivalent volumes of DMSO were used as vehicle controls. Reactive Oxygen species were measured after 8hrs Nuak1 inhibition using CellROX Deep Red or MitosOX reagents (Thermo) according to the manufacturers directions, followed by FACS analysis. For cell death measurements, cells were trypsinized, quenched with 1% BSA followed by replacement of original supernatant, and centrifuged at 300 x G for 5mins; 200ul of Annexin binding buffer (10mM HEPES (PH 7.40, 140mM NaCl, 2.5mM CaCl\textsubscript{2}) and 2μl of Annexin V-APC (Biolegend 640920) were
added to the pellet and incubated for 15mins. Propidium iodide (PI, 10µg/ml) was added immediately prior to FACS analysis. Alternatively, cells were imaged by Incucyte (Essen Bio) time-lapse video-microscopy in the presence of Sytox green reagent (Thermo Fisher). For immunoblotting, whole cell lysates were prepared in RIPA buffer (150mM NaCl, 50mM Tris, pH 7.5, 1% NP-40, 0.5% sodium deoxycholic acid, 1% SDS, plus complete protease and phosphatase inhibitor cocktail) followed by sonication (40% Amp for 5s). Cytoplasmic and Nuclear fractions were prepared in low salt buffer (20mM KCl, 10mM HEPES, pH 7.5, 1mM MgCl2, 1mM CaCl2, 0.1% Triton X-100) followed by centrifugation at 3300 rpm for 3min. NUAK1 (CST 4458, 1:750); NUAK2 (Hs: MRC, S225B, Mm: CST 4100); NFR2 (Novus NB100-80011, 1:1000); pMYPT1 (MRC S5087, 1:400); total MYPT (BD 612164, 1:1000); β-Actin (Sigma A5451, 1:5000); Lamin A/C (Santa Cruz, 6215), Keap1 (Santa Cruz, 15246); phosphor AMPK substrate (CST 5759) were used as primary antibodies. Secondary horseradish peroxidase conjugated antibodies (α-mouse IgG NA931V; α-rabbit NA934V, both GE Healthcare; α-goat IgG, Vector Labs PI-9500) were detected by chemiluminescence (Pierce ECL western blotting substrate 32106). For immuno-precipitations (IPs), 2.5x10^6 cells were seeded per 15cm dish. Next day, 5ug of NFR2-Flag or empty vector was transfected using Lipofectamine 3000 reagent (1:1.8 ratio for Lipofectamine, 1:2 for p3000 reagent). 48hrs post transfection, cells were trypsinized and 5x10^6 cells were seeded per 15cm dish. Cells were treated with 10µM HTH or DMSO for 8hrs, then washed with ice cold PBS and scraped in 400µl of NP-40 lysis buffer (150mM NaCl, 50mM Tris Ph7.5, 1mM EDTA, 1mM EGTA, 1% NP-40, plus complete protease and phosphatase inhibitor cocktail). Lysates were incubated on ice for 10min and centrifuged at 12k rpm for 10min and the supernatant was used for IP. 1.5mg of total protein was used per condition. Lysates were incubated with Flag-M2 resin (20μl /µg of protein) overnight. Beads were pelleted at 3000rpm/5 minutes and washed 3X with the lysis buffer (3000 rpm/5min/4°C). IP’ed proteins were eluted in 60μl of 1x Laemlli buffer. The following siRNAs were used at 20nM, except where noted: NUAK1 D-004931-01-002 (40nM, Dharmacon) S100108402 (10nM, Qiagen); NUAK2 S102660224 (Qiagen); NFR2 S103246950, S104223009 (Qiagen); KEAP1 S104155424, S103246439 (Qiagen); PTEN S10301504, S103048178 (Qiagen). For Dimedone detection of Cysteine oxidation, USOS cells transiently overexpressing FLAG-tagged NUAK1 were treated with H2O2 for 5 minutes, then lysed in RIPA buffer containing 1mM Dimedone (Sigma, D153303) followed by α-FLAG IP. Dimedone incorporation was detected using α-Dimedone antibody (Millipore, 07-2139). Iodo-acetamide labeling was performed similarly by addition of 55mM labeled (35C2H2H1NO; Sigma-Aldrich/ Merck KGaA, 721328) or unlabeled (C2H2NO; Sigma-Aldrich/ Merck KGaA, I6125) iodoacetamide in RIPA buffer, followed by anti-FLAG IP. IPs were washed twice in lysis buffer, followed by H2O2, prior to combining H2O2 treated and untreated samples for MS analysis (see below). Label incorporation was normalized to the level of IP’ed NUAK1, measured by immunoblotting of 10% of each IP.

Gene expression analysis
U2OS cells were depleted of Nuak1 by shRNA-4977 as previously described (9) and selected on puromycin for 48hrs. Control cells were similarly selected after infection with non-targeting shRNA expressing retrovirus. SW480 and HCT116 cells were depleted of NFR2 or NUAK1 by siRNA. 24hrs after re-seeding in the absence of selection, total RNA was isolated using the RNEasy Mini Kit (Qiagen) according to manufacturer’s instructions and DNA was depleted with the RNase-Free DNase Set (Qiagen). RNA-integrity was checked using the RNA ScreenTape assay (Agilent Technologies) and cDNA was synthesized with the TruSeq Stranded mRNA Library Prep Kit (Illumina). Following library quantification (D1000 ScreenTape, Agilent Technologies), libraries were standardized to 10nM, denatured, diluted to 10pM and analyzed by paired-end sequencing using an Illumina NextSeq500 platform. RNA-Sequencing reads were aligned to the GRCh38 version of the human genome or the GRCm38 version of the murine genome and differential expression determined using DESeq2 (59). Pathway modulation analysis was performed using Metacore.
GeneGO (Thompson Reuters). For analysis of individual genes, RNA was isolated using TRIZOL (Invitrogen) as per manufacturer’s directions. cDNA was synthesized using Quantitect reverse transcription kit (Qiagen 205313) followed by real time PCR using SYBR Green method (VWR QUNT95072). The following primer sets were used to detect indicated mRNA transcripts:

**Human**

GCLC F: 5’atgcatgaacaacggagagag; R: 5’tgatccaagaagctggttcttc
GCLM F: 5’gttggaacagctgtatcgttg; R: 5’gttggaacagctgtatcgttg
GSHR F: 5’atgcatgacgcaacacgtc; R: 5’cttccagcgcgaacagaggt
MGST F: 5’accaccaactgtatcgttg; R: 5’gcctcttgaggaagtaactca
TXN F: 5’ttcagccctgctgctcag; R: 5’ggctctctgaaacagcttct
β-ACTIN F, 5’ccaacccgagaagatgta; R: 5’ccagagcctacagggtag
NUAK1 F: 5’acatgatctctaactctgctg; R: 5’actcagcggaaagtcaagc

**Mouse**

Gclc L: 5’agatgataagaacagggagagag; R: 5’tgacccctaatgggattcttc
Gclm L: 5’tgactcacaatccctcctgtt; R: 5’tgacccctaatgggattcttc
Gshr L: 5’ctatgaccaacatctcctgtt; R: 5’tcctctttgctagcctgctt
Mgst L: 5’gctctctctcttcttc; R: 5’gcctctttgctagcctgctt
Txn L: 5’tgaagctgtcagagcagaa; R: 5’agaagctcagacagcag
B2m F: 5’aggccgacattaagcagctcag; R: 5’ccgctctttgctagcctgctt
Nuak1 F: 5’agagccgacccacacccctctc; R: 5’tcttgagctcggagagc

A human CRC tissue micro-array comprising 650 tissue cores was stained for NUAK1 mRNA expression by RNA-Scope (as described above) and scored blindly using Halo image analysis software (Indicalab). Omitting 47 results that failed quality control (undetectable PP1β expression), results were subdivided into equal quartiles from low to high NUAK1 expression and P values were determined by Chi-Square test.

**Proteomic analysis**

**SILAC labeling**: U2OS cells were cultured in light (13C6,15N4 L-arginine and 13C6,15N2 L-lysine, Sigma) and heavy (13C6,5N4 L-arginine and 13C6,5N2 L-lysine, Cambridge Isotope Laboratories) SILAC medium (SILAC DMEM, Life Technologies) supplemented with 10 KDa dialysed serum (Sigma) until full labeling (>98%) of the proteome was reached. For “forward analysis” heavy labeled cells were treated for 1hr with 10 μM HTH-01-015, and light labeled cells were vehicle treated. Cells were then harvested and lysates mixed in equal amounts. For the reverse replicate experiment, light labeled cells were treated for 1hr with 10 μM HTH-01-015, and heavy labeled cells were vehicle treated. **Sample Preparation**: 1.5 mg of each cell lysate from light and heavy SILAC labeled cells were mixed 1:1, light CtI : heavy HTH in the forward experiment and light HTH and heavy CtI in the reverse experiment. Proteins were precipitated overnight at -20 C in acetone, re-dissolved in 8M Urea, 0.1 M TrisHCl pH 8.5 buffer with phosphatase inhibitors (Halt phosphatase cocktail, Thermo Scientific) and digested with Lys-C (Alpha Laboratories) and Trypsin (Promega) using Filter-Aided Sample Preparation (FASP) (60). To remove salts, peptides were loaded onto C18 Sep-Pak column (Waters) and eluted with increasing concentration of acetonitrile (ACN, 10%, 15%, 20%, 25%, 30%, 40%, 60%) in 01% trifluoroacetic acid. ACN was removed using a speed vacuum centrifuge and peptides were resuspended in MOPS 50 mM, sodium phosphate 10 mM, sodium chloride 50 mM pH 7.2. Fresh ACN was added to 30% final concentration and TFA to pH down to 2.5. The enrichment for phosphorylated peptides was performed incubating the peptide solution with TiO2 beads, 5:1, peptide:TiO2, as previously described (60). Four subsequent incubations with TiO2 were performed. Peptides were eluted from the TiO2 beads using a solution 15% ammonium hydroxide 40% ACN and loaded onto a C18 StageTip (62). Peptides were eluted from StageTip with 80% ACN, speed vac and resuspended in 1% ACN, 0.05% TFA for MS analysis. Peptides
recovered from the four incubations were run separately at the MS. **MS analysis:** Digested peptides were injected on an EASY-nLC system coupled on line to a LTQ-Orbitrap Elite via a nanoelectrospray ion source (Thermo Fisher Scientific). Peptides were separated using a 20 cm fused silica emitter (New Objective) packed in house with reversed-phase Reprosil Pur Basic 1.9 µm (Dr. Maisch GmbH) and eluted with a flow of 200 nl/min from 5% to 25% of buffer containing 80% ACN in 0.5% acetic acid, in a 190 min linear gradient. The top ten most intense peaks in the full MS were isolated for fragmentation with high collision energy dissociation. MS data were acquired using the XCalibur software (Thermo Fisher Scientific) and .RAW files processed with the MaxQuant computational platform (63) version 1.5.0.36 and searched with the Andromeda search engine (64) against the human UniProt database (65) (release-2012 01, 88,847 entries). MaxQuant was run with the following settings: To search the parent mass and fragment ions we required a mass deviation of 4.5 ppm and 20 ppm. The minimum peptide length was 7 amino acids and maximum of two missed cleavages and strict specificity for trypsin cleavage were required.

Carbamidomethylation (Cys) was set as fixed modification, and oxidation (Met), N-acetylation and phosphoSTY as variable modifications. For peptide and phosphorylation site identification, a false discovery rate (FDR) of 1% was required. The re-quantification and match between runs features were enabled and the relative quantification of the peptides against their SILAC-labeled counterparts was performed by MaxQuant. For phosphorylation sites to be quantified, we required at least two ratio counts. The MaxQuant output file Phospho (STY)Sites was analyzed with the Perseus software (66), the reverse and contaminant hits were excluded and only class I phosphorylation sites (localization probability = probability that the phosphorylation site has been accurately localized > 0.75 and score difference > 5) used for the analysis. Raw MS data is available via the PRIDE repository under accession number PXD008229. **Cysteine oxidation:** tryptic peptides were separated by nanoscale C18 reverse-phase liquid chromatography on an EASY-nLC II 1200 (Thermo Scientific) coupled online to a Q-Exactive HF mass spectrometer (Thermo Scientific) and data acquired using the XCalibur software (Thermo Fisher Scientific). The .RAW files were processed with the MaxQuant computational platform version 1.6.0.16 as described above, but with Cysteine carbamidomethyl Heavy and Light as variable modifications. The Oxidation (M)Sites.txt was analyzed with the Perseus software.

**Kinase Assays**

GST-tagged full length human NUAK1 (product number 02-126) was purchased from Carna Biosciences, Japan. Kinase assays were performed using an IMAP fluorescence polarization assay format (Molecular Devices Inc.). a titration of kinase from 470nM down to 45nM was incubated for 60 min at room temperature with 100 nM 5Fam-LKKQLSTLYL, NRF1-derived peptide or 5Fam-VSRSGLYRSPENLNRPR, CDC25C-derived peptide (synthesized by Alta Biosciences, University of Birmingham UK) in the presence of 50 µM ATP and 50 mM MgCl2 in 20 mM HEPES buffer (pH 7.5) containing 0.01% Brij-35. Reactions were stopped by adding 2 assay volumes of 0.25% (v/v) IMAP progressive binding reagent in 1x progressive binding buffer A for the NRF1 peptide or 0.16% (v/v) IMAP progressive binding reagent in 85:15% IMAP progressive binding buffer A: Buffer B for the CDC25C peptide. After 60 min incubation to allow binding reagent to bind phosphorylated peptide, fluorescence polarization was measured on a Tecan Infinite M1000 Pro plate reader at excitation (470 nm) and emission (530 nm) wavelengths. Net fluorescence polarization values were calculated by subtractions of the control samples with no ATP.
References (continued from main text)


Figure S1

A. NUAK1 ISH

B. No. of Cases

C. NUAK1 mRNA

D. Overall Survival

E. NUAK1 mRNA

F. Overall Survival

G. Alterations in CRC (TCGA)

H. Western Blot

I. SW480

J. SW480

K. SW480

L. SW620

M. SW620

N. SW620

O. HCT116

P. HCT116

Q. HCT116
Figure S1 (continued)

**L**

<table>
<thead>
<tr>
<th>siNUAK1</th>
<th>siCon #1</th>
<th>#2</th>
</tr>
</thead>
<tbody>
<tr>
<td>NUAK1</td>
<td>NUAK2</td>
<td>AMPK α1/α2</td>
</tr>
<tr>
<td>100</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>70</td>
<td>70</td>
<td>70</td>
</tr>
<tr>
<td>55</td>
<td>55</td>
<td>55</td>
</tr>
<tr>
<td>42</td>
<td>42</td>
<td>42</td>
</tr>
</tbody>
</table>

**M**

<table>
<thead>
<tr>
<th>% of cells</th>
<th>AV/PI</th>
<th>AV</th>
</tr>
</thead>
<tbody>
<tr>
<td>- 2.5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>***</td>
<td>***</td>
</tr>
</tbody>
</table>

**N**

<table>
<thead>
<tr>
<th>p-MYPT</th>
<th>MYPT</th>
<th>Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>SW480</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SW620</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HCT116</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**O**

<table>
<thead>
<tr>
<th>% of cells</th>
<th>AV/PI +ive</th>
<th>AV +ive</th>
</tr>
</thead>
<tbody>
<tr>
<td>ns</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**P**

<table>
<thead>
<tr>
<th>MEFs</th>
<th>pMypt1</th>
<th>Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>HTH</td>
<td>WZ (10μM)</td>
</tr>
<tr>
<td>180</td>
<td>180</td>
<td>130</td>
</tr>
<tr>
<td>130</td>
<td>130</td>
<td>43</td>
</tr>
</tbody>
</table>

**Figure S1 (continued)**
Figure S1: NUAK1 is associated with tumor progression and reduced OS in human CRC. Pertains to Figure 1.

A) Representative examples of NUAK1 levels in human CRC, detected by RNA-Scope ISH (black dots, highlighted in Q1 and Q2 by arrowheads) counterstained with hematoxylin. Scale bar =10µm. B) Summary of NUAK1 mRNA detection in a human CRC TMA. Data were divided into equal quartiles from lowest (Q1) to highest (Q4) expression and graphed by Dukes’ stage. Chi Square test P value shown. C) Box & whisker plots of NUAK1 mRNA levels in human CRC separated by risk group. Blue = low risk, Red = high risk. T-test P value shown. D) Overall survival of human CRC patients separated by high versus low NUAK1 expression. Logrank P value, hazard ratio (HR) and 95% confidence interval (CI) shown. (C & D) Data mined from Jorissen et al and analyzed via Metabase SurvExpresss. E) Box & whisker plots of NUAK1 mRNA levels in human CRC separated by risk group. Blue = low risk, Red = high risk. T-test P value shown. F) Overall survival of human CRC patients separated by high versus low NUAK1 expression. Logrank P value, hazard ratio (HR) and 95% confidence interval (CI) shown. (E & F) Data mined from Smith et al and analyzed via Metabase SurvExpresss. G) Analysis of genomic alteration and mRNA over/underexpression of NUAK1 and NUAK2 in the TCGA cohort of Colorectal Adenocarcinoma, accessed via cBioportal. H) Immunoblots show relative expression of NUAK1, NUAK2 and MYC across the cell lines used in this study. Lysates from 3x10⁶ cells per cell line were analyzed. I) Growth curves of CRC cell lines treated with 5µM HTH-01-015, measured by Incucyte time-lapse video microscopy. Mean & SD of 4 technical replicates shown. Asterisks indicate significance (Unpaired T-test). J) Growth curves of CRC cell lines upon siRNA-mediated depletion of NUAK1, counted by CASY cytometry. Mean & SE of 3 technical replicates from 1 of 3 experiments shown. Asterisks indicate significance (Unpaired T-test). K) Growth curves (Incucyte) of CRC cell lines upon depletion of NUAK1 using a second siRNA distinct from (J). Mean & SE of 3 technical replicates from 1 of 3 independent experiments shown. L) Immunoblots of NUAK1, NUAK2 and AMPKα1/α2 expression upon depletion of NUAK1 in CRC cell lines using 2 independent siRNAs (from J & K). M) Apoptosis measured in human CRC lines after 48hrs of combined inhibition of NUAK1 and NUAK2 with the indicated concentrations of WZ4003. Red bars indicate AnnexinV/Propidium Iodide (AV/PI) double positive cells; black bars indicate AnnexinV positive cells. Mean and SEM of 3 independent experiments shown; asterisks show significance (1-way ANOVA & post-hoc Tukey test, relative to vehicle controls (-)). N) Phospho-MYPT1544S immunoblots after 8hr treatment with WZ4003 in the indicated cell lines. O) Apoptosis induced in MEFs 48hrs after treatment with 10µM HTH-01-015 or WZ4003. Red bars indicate AnnexinV/Propidium Iodide
(AV/PI) double positive cells; black bars indicate AnnexinV positive cells. Mean and SEM of 3 independent experiments shown; asterisks show significance (1-way ANOVA & post-hoc Tukey test, relative to vehicle controls (-)). Ns = not significantly increased relative to untreated controls.

**P** Phospho-MYPT$^{545}$ immunoblots after treatment of MEFs with NUAK1 inhibitors for 1hr.
Figure S2

A

Villin-CreER

Apc FL/+  

Tamoxifen

Time

Isl-KRasG12D

Nuak1 FL/FL

B

No. of SI Tumours/Mouse

VAK  VAKN

p=0.225

C

Total SI Tumor Burden

VAK  VAKN

p=0.1518

D

Percent survival (%)

Days Post Induction

VAK  VAKN

p=0.355

E

NUAK1 expression relative to B2M (%)

T  N  T  N  T  N  T

VAK  VAKN
<table>
<thead>
<tr>
<th></th>
<th>VAK</th>
<th>VAKN</th>
</tr>
</thead>
<tbody>
<tr>
<td>H&amp;E</td>
<td><img src="image1" alt="H&amp;E Image" /></td>
<td><img src="image2" alt="H&amp;E Image" /></td>
</tr>
<tr>
<td>p-Erk</td>
<td><img src="image3" alt="p-Erk Image" /></td>
<td><img src="image4" alt="p-Erk Image" /></td>
</tr>
<tr>
<td>β-Catenin</td>
<td><img src="image5" alt="β-Catenin Image" /></td>
<td><img src="image6" alt="β-Catenin Image" /></td>
</tr>
<tr>
<td>Nuak1 (ISH)</td>
<td><img src="image7" alt="Nuak1 (ISH) Image" /></td>
<td><img src="image8" alt="Nuak1 (ISH) Image" /></td>
</tr>
</tbody>
</table>
Figure S2: Inefficient deletion of NUAK1 in the small intestine and selective pressure to retain NUAK1 in large intestine tumours. Pertains to Figure 2.

A) Schematic of alleles used to generate VAK and VAKN mice. CreER was transiently activated by a single injection of Tamoxifen to initiate allele recombination. Over time, loss of the wild-type (non-floxed) Apc allele allows sporadic tumor development in the gut. B) Number of small intestine (SI) tumors per mouse in VAK (N=12) and VAKN (N=16) mice, harvested at end-point. C) Total SI tumor burden in mice of the indicated genotypes. D) Kaplan Mayer survival plot of VAK (N=14) and VAKN (N=22) mice, measured from day of Tamoxifen injection. P value shown for Logrank Test. E) Nuak1 mRNA in individual SI tumors and adjacent normal SI tissue taken from individual VAK and VAKN mice, as indicated. Error bars represent SEM of technical triplicates. F) Representative images of IHC analysis of nuclear beta-Catenin and ERK phosphorylation in tumours from VAK & VAKN mice. Scale bars = 100μm (low res) & 20μm (high res). G) Representative images show ISH detection of Nuak1 mRNA (red dots) in 6 randomly selected tumors of VAKN mice, along with 2 from VAK controls.
Figure S3: No effect of Nuak1 deletion in otherwise wild-type gut. Pertains to Figure 2.
A) Representative images of small intestine from wild-type (top panels) or homozygous floxed Nuak1 (lower panels) mice harvested 6 days after tamoxifen dependent activation of CreER in VN mice, stained for histology (H&E); proliferation (BrdU); apoptosis (Cleaved Caspase 3); and differentiation (Lysozyme and PAS). N=3 (Nuak1\textsuperscript{wt/wt}) and 3 (Nuak1\textsuperscript{FL/FL}). Scale bar = 100\mu m. B) Representative images of large intestine from mice as in (A). Scale bar = 100\mu m. C) Quantification of staining from (A & B). Black bars = Nuak1\textsuperscript{wt/wt}; red bars = Nuak1\textsuperscript{FL/FL}. Mean and SEM shown; ns = not significant. D) Representative images of small intestine from from wild-type (WT), Villin-CreERT\textsuperscript{2};Apc\textsuperscript{fl/fl}; (VA) or Villin-CreERT\textsuperscript{2};Apc\textsuperscript{fl/fl};Nuak\textsuperscript{fl/fl} (VAN), stained for histology (H&E) and proliferation (BrdU) N=3, Scale bar = 100\mu M. E) Organoid cultures from wild-type intestines treated with vehicle (i) or 2.5\mu M (ii); 5\mu M (iii) or 10\mu M (iv) Nuak1 inhibitor HTH-01-015 for 48hrs. Scale bar = 100\mu m.
Figure S4: Deletion of Nuak1 suppresses NRF2-dependent gene expression in MEFs. Pertains to Figure 3.

A) Schematic representation of selected NRF2-dependent anti-oxidant defense genes modulated upon depletion of NUAK1. B) mRNA expression of selected NRF2 target genes in *Nuak1*<sup>FL/FL</sup> (left panel) and *Nuak1*<sup>WT/WT</sup> (right panel) MEFs after Adeno-CRE infection. Data are presented as percent of levels measured in uninfected controls. Mean and SEM of 3 independent experiments are shown. Asterisks denote significance; ns = not significant (unpaired T-test). C) Immunoblot confirms deletion of *Nuak1* in Adeno-CRE infected *Nuak1*<sup>FL/FL</sup> MEFs. D) 4-OHT inducible deletion of Nuak1 in Nuak1<sup>FL/FL</sup> MEFs stably infected with CreER<sup>T2</sup>-expressing retrovirus. E) Apoptosis levels measured in H₂O₂-treated (500μM, 48hrs) *Nuak1*<sup>FL/FL</sup> MEFs, with (OHT) and without (VC) CreER mediated deletion of *Nuak1*. Similar results were observed after Adeno-CRE mediated deletion of *Nuak1*. Mean and SEM of technical triplicates from a representative experiment are shown. F) Cumulative dead cell counts, measured by uptake of Sytox green reagent in cultures of SW480 (left) and SW620 (right) cells, after treatment with HTH-01-015 in the presence or absence of Trolox (500μM). Results are representative of 2 experiments for each cell line. Error bars reflect SD of technical triplicates. G) Rescue of small intestine derived spheroids from Nuak1 inhibitor-induced death by exogenous anti-oxidant Trolox, as per main Figure 3L. Asterisks indicate significance (2-way ANOVA and Tukey’s post-hoc test). H) Representative FACS detection of cytosolic H₂O₂ levels measured by CellRox™ fluorescence after 8hrs HTH-01-015 (10μM) treatment in the presence of Trolox (500μM). I) Mean (±SEM) CellRox fluorescence intensity in SW480 cells (technical triplicates) treated with HTH-01-015 and/or Trolox as per (H). Representative of 2 independent experiments.
Figure S5

A) Western blot images showing NRF2-Flag binding in EV and NRF2-Flag conditions withvc and HTH treatments. Input and FLAG-IP lanes are presented. 

B) Graph showing fluorescence polarization of CDC25C pep and NRF2 peptide with increasing [NUAK1] (ug/well).

C) Western blot images showing NRF2 and Actin expression in siNT and siNUAK1 conditions with 0-20 minutes of CHX treatment.

D) Western blot images showing NRF2, Lamin A/C, and Tubulin expression in SW480, HCT116, and SW620 cell lines with CE and NE treatments.

E) Western blot images showing NRF2, Lamin A/C, and Actin expression with H2O2 treatment and siNUAK2 and siNUAK2-+ conditions.

F) SILAC protocol diagram with steps for Light (0,0) and Heavy (8,10) SILAC protein mixture, Protein digestion (FASP), Phospho-Peptide enrichment (TiO2), High Resolution MS, and Data analysis (Maxquant & Perseus).

G) Western blot images showing NRF2 and Actin expression with GSK3βi treatment and siNUAK1, Si Nuak1, and Si Nuak1+Gski conditions.

H) Western blot images showing Nrf2, PTEN, and Lamin A/C expression with siPTEN and H2O2 treatment and siNUAK1 conditions.
Figure S5: Regulation of NRF2 by NUAK1 is indirect. Pertains to Figure 5.

A) Anti-Phospho-pan-AMPK-substrate immunoblot of whole cell extracts (left 4 lanes) and anti-FLAG immunoprecipitates (right 4 lanes) from U2OS cells transfected with FLAG-tagged NRF2 or empty vector (ev), as indicated. B) In vitro kinase activity of commercially purified NUAK1 towards a NRF2 peptide containing a putative AMPK consensus motif. CDC25C peptide serves as positive control. Error bars reflect technical triplicates. C) NRF2 immunoblot upon Cyclohexamide (chx) treatment of SW480 cells for the indicated times with and without depletion of NUAK1. Lower panels show Image J quantification of NRF2 protein from the blot presented D) NRF2 immunoblots in cytosolic (CE) and nuclear (NE) extracts of CRC cell lines treated with/without 500µM H2O2 for 30 minutes. Lamin A/C and Tubulin immunoblots indicate purity of sub-cellular fractionation. E) Depletion of NUAK2 suppresses peroxide-induced nuclear accumulation of NRF2 in SW620 cells. Immunoblot (right panel) confirms selective depletion of NUAK2 by siRNA. F) Schematic of SILAC based phospho-proteomic analysis of U2OS cells after treatment with HTH-01-015. G) NRF2 immunoblot of NUAK1 depleted SW480 cells, treated with and without GSK3β inhibitor (CHIR99021, 3µM for 6hrs), followed by cyclohexamide (100pg/ml) for the indicated durations. Note that the NUAK1-depleted lanes without GSK3βi treatment are the same shown in panel (B). Lower panel shows quantification as per (B). H) Depletion of PTEN rescues nuclear accumulation of NRF2 in NUAK1 depleted SW480 cells. Blots are representative of 2 independent experiments. Right panel confirms depletion of PTEN.
Figure S6

A

<table>
<thead>
<tr>
<th></th>
<th>WT</th>
<th>shNuak-612</th>
<th>shNuak-1533</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dox 1ug/ml</td>
<td>-</td>
<td>+</td>
<td>+/−</td>
</tr>
</tbody>
</table>

B

1. Tamoxifen
2. DSS
3. Tissue Regeneration
4. Sporadic Tumor Formation

Villin-CreER
Apc FL/+ 
Rosa26-lsl-rtTA
Rosa26

Tre-sh-Nuak1

shRNA-Nuak1a/b

Doxycycline
Figure S6

Normal colon

Colon Tumours
Figure S6

D

Untreated

Dox (2days)

mouse 1

mouse 2

mouse 3

mouse 4

E

F

Vil-CreER\textsuperscript{T2};Apc\textsuperscript{+/FL} + DSS + 1wk Doxycycline

NAC

ctrl

shNuak\textsuperscript{1533}

G

Vil-CreER\textsuperscript{T2};Apc\textsuperscript{+/FL}

+ DSS + 1wk Doxycycline

No. of LI Tumors

Total Tumor Burden

Indiv. Tumor Size
Figure S6: NAC has no effect on NUAK1-replete colorectal tumors. Pertains to Figure 7.

A) Nuak1/2 immunoblots upon treatment of MEFs carrying either of the shNuak1-612 or shNuak1-1533 alleles or control MEFs (WT) with 1µg/ml doxycycline for 72hrs. B) Schematic of the experimental setup for main Figure 7 and below: (1) Transient activation of CreER by Tamoxifen injection deletes the floxed Apc allele and initiates gut-restricted expression of rtTA3. (2) Mice are administered dextran sodium sulfate (DSS) for 5 days to drive accelerated turnover of colonic epithelium, leading to sporadic loss of the remaining wild-type Apc allele (3) and tumour initiation. 64 days after Tamoxifen injection, mice were administered doxycycline to induce expression of shRNA targeting Nuak1 (4). Mice were harvested for examination after 1 week of Nuak1 depletion (day 70 post-induction). C) RNA-Scope ISH shows continued expression of Nuak1 mRNA in tumors that were harvested from the doxycycline-induced shNuak-612-expressing VA mouse encircled in Fig. 6A (panel iii), and a residual tumor from an shNuak-1533-expressing mouse (panel iv). Panels i & ii show adjacent normal tissue from the same gut shown in iii. Arrowheads point to examples of specific signal. Scale bars = 50 µm (panels i, iii & iv) and 30 µm (panel ii). Panels v-viii show variable levels of continued NUAK1 expression in additional tumors that persist after 7 days of RNAi induction (ie. “escapers” from effective RNAi). D) Licor ROSStar™ ex vivo detection of ROS in colonic tumors induced to express shNUAK1-1533 for 2 days, compared with un-induced controls. E) RNA-SEQ measurement of selected NRF2 target genes in tumors (N=6) from mock-treated control mice (black bars) compared with shNuak1-1533 expressing tumors (N=6, red bars), harvested after 2 days of shRNA induction. Data are normalized to the Mean expression of control tumors. Mean and SEM shown. F) Whole-mount examples of large intestines from experimental mouse, expressing shNUAK1-1533 for 1 week where indicated, in the presence or absence of NAC anti-oxidant supplementation. Arrowheads point to individual tumors, the dashed line indicates a continuous string of tumors. G) NAC has no effect on the number of tumors per mouse, the total tumor burden, or the size of individual tumors in Nuak1-replete mice. Graphs depict Mean (blue bars) and SEM (red bars) of the indicated parameters in mice treated (N=3) or not (N=7) with NAC. Note that the data from untreated mice (nt) are the same as in main figure 6A (-). No parameter showed a significant difference (Mann-Whitney test).
<table>
<thead>
<tr>
<th>Rank</th>
<th>2</th>
<th>4</th>
<th>6</th>
<th>8</th>
<th>10</th>
<th>12</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>41</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>42</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>43</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>46</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>47</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>48</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>49</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Cell cycle_Influence of Ras & Rho proteins on G1/S transition
2. Neurogenesis_NGF/TrkA MAPK-mediated signaling
3. Transcription_Hif-1 targets
4. Cell adhesion_Chemokines & adhesion
5. IGF family signaling in colorectal cancer
6. Oxidative phosphorylation
7. Apoptosis and survival_NGF/TrkA PI3K-mediated signaling
8. Signal transduction_PTEN pathway
9. Cytoskeletal remodeling_Regulation of actin cytoskeleton organization by the kinase effectors of Rho GTPases
10. Development_IGF-1 receptor signaling
11. Aberrant B-Raf signaling in melanoma progression
12. Cell adhesion_Integrin-mediated cell adhesion & migration
13. Signal transduction_mTORC2 downstream signaling
14. Ligand-independent activation of Androgen receptor in prostate cancer
15. HBV signaling via protein kinases leading to HCC
16. Ovarian cancer (main signaling cascades)
17. Development_WNT signaling pathway Part. 2
18. Stellate cells activation and liver fibrosis
19. Apoptosis & survival_BAD phosphorylation
20. Neurophysiological process_Receptor-mediated axon growth repulsion
21. Transcription_Androgen Receptor nuclear signaling
22. IL-6 signaling in multiple myeloma
23. Cytoskeletal remodeling_Integrin outside-in signaling
24. Normal & pathological TGF-beta-mediated regulation of cell proliferation
25. Immune response_IL-4 signaling pathway
26. Signal transduction_AKT signaling
27. Signal transduction_mTORC1 downstream signaling
28. Development_EGFR signaling pathway
29. Cell cycle_Regulation of G1/S transition (Part 1)
30. Androgen receptor activation and downstream signaling in Prostate cancer
31. Development_Regulation of cytoskeletal proteins in oligodendrocyte differentiation & myelination
32. Immune response_IL-3 signaling via ERK and PI3K
33. Main growth factor signaling cascades in multiple myeloma cells
34. Cell cycle_Start of DNA replication in early S phase
36. Development_Thrombopoietin-regulated cell processes
37. Translation_Regulation of EIF2 activity
38. Translation_Regulation of EIF4 activity
39. Immune response_IFN-alpha/beta signaling via PI3K & NF-KB pathways
40. Development_Growth factors in regulation of oligodendrocyte precursor cell proliferation
41. NRF2 regulation in oxidative stress response
42. Immune response_M-CSF-receptor signaling pathways
43. Development_TGF-beta receptor signaling
44. Development_Adenosine A2A receptor signaling
45. Cytoskeletal remodeling_Regulation of actin cytoskeleton nucleation & polymerisation by Rho GTPases
46. Apoptosis & survival_Granzyme B signaling
47. Tau pathology in Alzheimer disease
48. Cell adhesion_Histamine H1 receptor signaling in the interruption of cell barrier integrity
49. Regulation of lipid metabolism_Insulin signaling: generic cascades
50. Development_PIP3 signaling in cardiac myocytes
Table S1: Analysis of biological pathways modulated by depletion of either NRF2 or NUAK1 in SW480 cells. Metacore GeneGO analysis shows the pathways most significantly regulated (up or down) upon depletion of NRF2 (blue bars) or NUAK1 (orange bars), ranked by p-value (-log).
<table>
<thead>
<tr>
<th>Rank</th>
<th>2</th>
<th>4</th>
<th>6</th>
<th>8</th>
<th>10</th>
<th>12</th>
<th>-log(pValue)</th>
<th>siNUAK1</th>
<th>siNRF2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2.429e-2</td>
<td>2.495e-13</td>
<td>3.250e-3</td>
<td>5.176e-13</td>
<td>5.469e-3</td>
<td>3.035e-11</td>
<td>ATP/ITP metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cell cycle_Start of DNA replication in early S phase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apoptosis &amp; survival_Role of PKR in stress-induced apoptosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>GTP-XTP metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CTP/UTP metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNA damage_ATM/ATR regualtion of G1/S checkpoint</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cell cycle_Role of APC in cell cycle</td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Apoptosis &amp; survival_Role of HTR1A signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Transcription_HIF-1 targets</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Immune response_Role of PKR in stress-induced antiviral cell repsonse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Cell cycle_Influence of Ras &amp; Rho proteins on G1/S transition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Transport_RAN regluation pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>NRF2 regulation of oxidative stress response</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Development_Regulaiton of telomere length &amp; cellular immortalization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ovarian cancer (main signaling cascades)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNA damage_NHEJ mechanims of DSBs repair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>CFTR folding &amp; maturation (normal &amp; CF)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Immune response_B cell antigen receptor (BCR) pathway</td>
<td></td>
<td></td>
</tr>
<tr>
<td>19</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Oxidative stress_ros-mediated activation of MAPK via inhibition of phosphatases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>20</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>DNA damage_Role of BRCA1 &amp; BRCA2 in DNA repair</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Neurogenesis_NGF/TrkA MAPK-mediated signaling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Aberrant B-Raf signaling in melanoma progression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Development_PDGF signaling via STATs and NF-KB</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Transcription_Sirtuin6 regulation &amp; function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Development_Positive regulation of STK3/4 (Hippo) pathway &amp; negative regulation of YAP/TAZ function</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S2: Analysis of most significantly down-regulated biological pathways after depletion of either NRF2 or NUAK1 in SW480 cells. Metacore GeneGO analysis shows the pathways most significantly down-regulated upon depletion of NRF2 (blue bars) or NUAK1 (orange bars), ranked by p-value (-log).
Table S3: NUAK1 inhibition suppresses inhibitory phosphorylation of GSK3β

Quantitative changes in phosphorylation of selected proteins after 1hr treatment of U2OS cells with 10µM HTH-01-015. GSK3 substrate motifs were identified by Perseus and/or Phosphosite Plus and verified where indicated (X) using the Princeton & KEA phospho-proteomic databases.